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Half a century of amyloids: past, present and
future†
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Thomas P. Davis, bl Marcus Fa¨ndrich,m Daniel Erik Otzen, n Matthew R. Chapman,o
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Amyloid diseases are global epidemics with profound health, social and economic implications and yet remain
without a cure. This dire situation calls for research into the origin and pathological manifestations of
amyloidosis to stimulate continued development of new therapeutics. In basic science and engineering, the
cross-b architecture has been a constant thread underlying the structural characteristics of pathological and
functional amyloids, and realizing that amyloid structures can be both pathological and functional in nature
has fuelled innovations in artificial amyloids, whose use today ranges from water purification to 3D printing. At
the conclusion of a half century since Eanes and Glenner’s seminal study of amyloids in humans, this review
commemorates the occasion by documenting the major milestones in amyloid research to date, from the
perspectives of structural biology, biophysics, medicine, microbiology, engineering and nanotechnology. We
also discuss new challenges and opportunities to drive this interdisciplinary field moving forward.
1. Introduction
The X-ray diffraction pattern of filamentous amyloid from
human liver and spleen, as described by Eanes and Glenner in
1968, contained ‘‘a sharp, intense ring at 4.75 Å overlaying a
diffuse halo at 4.3 Å and a broad and less intense ring at 9.8 Å’’.1
This followed the first report by Astbury et al. in 1934 on the
presence of the cross-b motifs in chicken egg proteins.2 Much
progress has been made since then. Within the realm of
structural biology, the cross-b structure of human amyloid first
revealed in that seminal study has underpinned our under-
standing (or the lack thereof) of the aggregation of amyloid
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proteins as well as their associated pathologies, from cerebral
amyloid angiopathy (CAA), tauopathies and synucleinopathies to
amyloid light-chain (AL) amyloidosis, transthyretin (TTR)
amyloidosis,3,4 amyotrophic lateral sclerosis (ALS) and rheuma-
toid arthritis (RA), and from the endogenous aggregation of
insulin and human islet amyloid polypeptide (hIAPP) to the
cross talk5 between amyloid proteins of different physiological
origins and the transmission of prion diseases6 across animal
species. Recent discovery of amyloid-like assemblies of meta-
bolites and their associated toxicities7 has shed new light on the
molecular mechanisms of human diseases, and blurred the
boundary between functional and pathological amyloid. As
bacterial multidrug resistance (MDR) has become a global health
crisis, understanding and exploiting the structural and patho-
logical roles of bacterial amyloid may offer new solutions for the
development of novel therapeutics. The recent finding of a gut–
brain neural circuit for nutrient sensory transduction8 points to
a connection between the gut microbiome and neurological
disorders,9 each of which is associated with amyloid architec-
tures. Major discoveries have been made in recent years and
months, implicating the gut microbiome as causative for obesity,
type 2 diabetes (T2D), neurological disorders, cancer, depression
and social behaviour.10–14
Amyloidosis refers to the accumulation and deposition of
amyloid fibrils,15 whose aggregation kinetics contains contribu-
tions of both primary and secondary nucleation,16 giving rise to
toxic intermediates of oligomers17,18 and protofibrils en route.
The amyloid state is characterized by steric zippers of the
amyloid cross-b spine,19 and the state is proposed to be acces-
sible by virtually all proteins under physiological or artificial
conditions. The crystalline form of amyloid proteins has recently
been identified as the absolute free-energy ground state20,21 over
the native or amyloid state of proteins. On a mesoscopic scale,
amyloid fibrils possess polymorphism, displaying a prevalent yet
nonexclusive left-handedness likely originated from the biased
chirality of amino acids.22 In engineering, amyloids of whey
proteins have found new applications in iron fortification, water
purification and in vivo sequestration of pathological amyloid
proteins,23–25 while functional amyloid-nanocomposites yield new
mechanical, thermal and electronic properties appealing to nano-
electronics, biotechnology and environmental engineering.26
To commemorate five decades of research since Eanes and
Glenner’s landmark study of human amyloid,1 here we reflect
on major milestones in the field of amyloid to date, shared
among the three major classes of amyloids: the pathological,
functional and artificial amyloids, and we discuss emerging
opportunities and grand challenges of the amyloid science
moving forward, from the perspectives of basic science, med-
icine and engineering (Fig. 1).
2. Amyloidosis, a prevalent yet peculiar
form of protein misfolding
Protein folding is one of the most perplexing problems in
molecular biology, despite many decades of extensive research.27,28
In short, protein folding is a complex process through which a
protein molecule acquires the unique native structure for carrying
out its specific biological functions. However, under certain patho-
logical conditions, proteins can misfold, resulting in structures
that expose the hydrophobic residues at the core of the folded
protein to the solvent. These misfolded proteins can self-assemble
into a variety of aggregate structures, including large, insoluble
fibrillar entities known as the amyloids.28 As mentioned above, a
number of diseases, including Alzheimer’s disease (AD) and T2D,
are associated with the presence of amyloid. Although proteins
involved in amyloid diseases are dissimilar in both sequences and
folds, the end-products of their aggregation bear striking structural
similarities including the fibrillar structure and cross-b backbone
as revealed by X-ray diffraction.1,29 Since many proteins that are
not associated with diseases also form amyloid fibrils, it has been
suggested that under certain conditions, any protein is capable of
forming an amyloid,30 indicating amyloidosis might be a prevalent
yet peculiar form of protein misfolding (i.e., amyloid formation
might represent a special type of evolving protein folding free
energy landscape, more below). In addition to protein misfolding,
it has also been recognized that some proteins have no single well-
defined tertiary structure. These proteins are termed intrinsically
disordered proteins (IDPs) which are often involved in cellular
signaling and regulation.31,32 Given the very large number of
degrees of freedom in an unfolded polypeptide chain, the protein
molecule has an astronomical number of possible conformations.
From one estimation, for a B100 residue protein, it would take
B1011 years to fold if the protein needs to explore all the possible
conformation states, while in reality it takesmerely milliseconds to
seconds for a typical protein to fold in vivo. This is called the
Levinthal paradox,33 proposed by Cyrus Levinthal five decades ago
in 1969. To overcome this paradox,33 several folding models, from
classical nucleation–propagation model to the folding funnel
model, have been proposed to complement experiments towards
better understanding of this complex folding process.
Fig. 1 Amyloidosis is a biophysical phenomenon of protein self-assembly
under natural or artificial conditions, underpinned by a ubiquitous cross-b
architecture (middle, in cyan). For over a half century, or arguably much
longer, investigations into the structures of pathological and functional
amyloids within the human anatomy (left, in blue), the microbiota (left,
in green) and beyond (right, in dark blue) have revealed their inner work-
ings as well as their entangled implications for biology, medicine and
engineering.
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The widely adopted protein folding funnel model has evolved
from both experiment and theory through the use of simplified
mechanical models developed by Wolynes, Onuchic, Dill and
colleagues35–37 and more recently by Mezzenga and coworkers.20,21
Fig. 2 illustrates the folding funnel which is a simplified 2D
representation of the very high-dimensional conformational space
accessible to a protein during its folding.34 The broad top of the
funnel represents a vast number of conformations present in the
fully unfolded or stretched state, while the narrow bottom of
the funnel depicts the unique native structure of the protein.35
The separation between the top and bottom of the funnel represents
other energies (solute enthalpy, solvent entropy and enthalpy)
contributing to each protein conformation. However, the cha-
perone effect (chaperonin-mediated folding) or multi-protein
co-folding effect (folding upon binding, etc.) is not included in
this picture due to its simplicity.35,36,38 Starting from the
ensemble of unfolded conformations, the folding funnel allows
many different pathways to proceed rapidly to the global free
energy minimum occupied by amyloids, recently refined into a
series of closely-positioned local minima, occupied by different
amyloid polymorphs, with the amyloid crystals alone occupying
the absolute minimum (for an extended discussion on the
energetic levels of different amyloid polymorphs see Section 4,
‘‘Mesoscopic structures of amyloids and the energy land-
scape’’).20,21 As the chain folds to lower energy conformations,
and before reaching the metastable local minima of the various
amyloid polymorphs, intermediate states along the sides of the
funnel are also populated. During this process, the kinetic traps
might hinder or promote formation of native structures depend-
ing on their depths and the barriers between the traps and next
energy minima. According to statistical mechanics, the number
and depth of local kinetic traps on the funnel landscape corre-
spond to the degree of frustration of the protein sequence.35
Following the concept of the folding funnel diagrams, an off-
pathway aggregation can be incorporated as second ‘‘aggregation
funnel’’.39 Like intramolecular folding, the association of two or
more non-native protein molecules can form an ‘‘amyloidosis
formation funnel’’ through intermolecular contacts (Fig. 2). The
process is largely driven by hydrophobic forces and primarily results
in the formation of amorphous structures (‘‘amorphous aggregates’’;
Fig. 2).34 Subsequently, aggregation can lead to the formation of
amyloid fibrils. These simplistic folding funnel models provide a
conceptual framework for understanding the complex process of
amyloid formation.20,21,34
Meanwhile, recent advances in experimental techniques
that probe amyloid formation at different stages have shed
light on the nature of both the kinetics and thermodynamics of
this complex process (more in the following sections). However,
many of the underlying molecular mechanisms and inter-
actions involved in amyloid protein/peptide misfolding and
aggregation pathways remain elusive. Computer simulations
performed at various levels of complexity ranging from simple
lattice models, models with continuum solvent, to all atom
models with explicit solvent have been used to offer complementary
and valuable insights that cannot be obtained by experimental
methods alone.40 In particular, the important role of water mole-
cules in promoting the formation of protofilaments, the basic
building blocks of amyloid fibrils, has been investigated using fully
atomic molecular dynamics (MD) simulations.41
Although the hydrophobic effect is known to have a signifi-
cant impact on protein self-assembly in water, the precise
mechanism of how it operates as well as the exact role of water
in facilitating this assembly remains controversial. In a recent
study,41 a model protofilament comprised of two parallel
b-sheets of Alzheimer Ab16–22 peptides (Ac-K16-L17-V18-F19-
F20-A21-E22-NH2) was employed to study amyloid formation
and the role of water molecules during the process using MD
simulation. Each b-sheet presented a distinct hydrophobic face
and a hydrophilic face, which together self-assembled into a
stable protofilament with a core consisting of purely hydro-
phobic residues (L17, F19, A21), with the two charged residues
(K16, E22) pointing to the solvent (Fig. 3A). The simulation
results revealed a subtle interplay between a water mediated
assembly and one driven by favorable energetic interactions
between specific residues forming the interior of the proto-
filament. Overall, the role of water during the assembly can be
viewed as ‘‘lubrication’’, namely it does not drive assembly but
rather facilitate proper packing of the hydrophobic surfaces in
the final stages of the assembly. In some of the MD trajectories,
a nanoscale dewetting (or drying) was also observed in which
water expulsion preceded hydrophobic collapse, providing a
strong driving force for the hydrophobic collapse and hydro-
phobic patch assembly. This can be attributed to the fact that
when two strongly hydrophobic surfaces, greater than 1 nm in
length, are brought together to a critical distance, a nanoscale
drying might occur between the two hydrophobic surfaces,
Fig. 2 Energy landscape of protein folding and aggregation. The purple
surface shows the multitude of conformations ‘funneling’ to the native
state via intramolecular contacts and the pink area shows the conforma-
tions moving toward amorphous aggregates or amyloid fibrils via inter-
molecular contacts. Both parts of the energy surface overlap. Aggregate
formation can occur from intermediates populated during de novo folding
or by destabilization of the native state into partially folded states and is
normally prevented by molecular chaperones. Toxic oligomers may occur
as off-pathway intermediates of amyloid fibril formation. Reproduced with
permission from ref. 34, copyright 2009 Nature Publishing Group.34
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resulting in a strong hydrophobic collapse.42,43 In the trajectories
where no nanoscale drying was observed, water expulsion and
hydrophobic collapse occurred roughly simultaneously (i.e., water
acting as ‘‘lubricant’’; Fig. 3).
The authors also studied the interaction energy decomposi-
tion to explore the contributions from various forces.41 Inter-
estingly, turning off the protein–water electrostatic interaction
only slightly slowed down the assembly speed without signifi-
cantly affecting the nanoscale drying (Fig. 3B). Conversely, if
the protein–water van der Waals attraction was switched off, a
strong dewetting transition and hydrophobic collapse takes
place in every simulation (Fig. 3B). These predictions were later
validated by experimental (and theoretical) studies of other
proteins with large hydrophobic patches.44 Overall, these com-
puter simulations demonstrate that in general, when attractive
van der Waals forces exist between the solute and solvent, these
forces, though individually small, can be sufficient to compen-
sate for the loss of hydrogen bonds due to the confinement of
water between the two plates. However, in extreme cases, such
as those highly hydrophobic and rough surfaces in-between the
amyloid protofilaments, some nanoscale dewetting might occur
which can provide strong driving force for the hydrophobic
collapse of amyloid peptides and their subsequent aggregation
and fibril formation.45
3. Towards atomic structures of
amyloid fibrils
As briefly introduced, amyloid fibrils are identified by a characteristic
X-ray fibre diffraction pattern which is termed cross-b (Fig. 4). This
pattern was first described for poached egg-white2 and later the data
from the silk egg stalk from the green lacewing fly was interpreted
to provide a detailed description of this repetitive structure.46 The
cross-b diffraction pattern gives a strong, sharp diffraction signal at
4.76–4.78 Å on the meridional (vertical) axis, which was interpreted
to arise from the distance between hydrogen bonded b-strands. On
the equator, (horizontal axis) several signalsmay be observed but the
dominant intensity is thought to arise from the spacing of several
b-sheets.47,48 For the silk from the egg stalk, the equatorial spacing
was only 5 Å. However, the spacing arising from amyloid fibrils
is more often larger to accommodate larger and more variable
side chains, from around 8 Å for polyQ containing peptides49,50
to 11–12 Å for those containing aromatic residues.51,52
Fig. 3 (A) Ab16–22 model protofilament (left panel). The initial structure used to start the MD trajectory with initial inter-b-sheet separation distance D0
of 1.28 nm. Front (a) and side (b) views are shown. Side chains are colored as follows: (K) red, (L) orange, (V) yellow, (F) green, (A) blue, and (E) violet. For
clarity, only water molecules in the interpeptide region have been shown. (c) The same structure after 1000 ps of unconstrained MD simulation at 300 K,
started from the structure shown in (a) and (b). (d) A single Ab16–22 peptide pair, one from each layer, is isolated from the protofilament shown in (c).
(B) Number of interpeptide water molecules versus interpeptide distance (right panel). (a–d) Plots for each of the four trajectories at 300 K where D0 =
1.28 nm. Trajectories (a) and (b) do not appear to show a dewetting transition, while trajectories (c) and (d) do. (e–h) The peptide–water van der Waals
interaction is turned off, and D0 = 2.38 nm. (i–l) The peptide–water electrostatic interaction is turned off, and D0 = 1.28 nm. Reproduced with permission
from ref. 41, copyright 2008 American Chemical Society.41
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Transmission electron microscopy was a valuable asset
and in 1959, Cohen and Calkins53 provided images of amyloid
fibrils extracted from liver. Eanes and Glenner showed the cross-
b diffraction pattern from amyloid extracted from liver and
spleen1 and then created ‘‘amyloid’’ in vitro from Bence Jones
proteins (excreted immunoglobulin light chains, LCs) or their
fragments.54 This disease, arising from the formation of LC-
derived amyloid fibrils, is now known as AL amyloidosis.55,56 As
early as 1946, Waugh reported precipitation of insulin under
high temperature, acidic conditions.57 In 1972, synthetic amy-
loid fibrils were made from insulin by repeated heating and
cooling under acidic conditions. This process generated long-
straight, unbranching fibrils that resisted degradation58 and
gave a cross-b diffraction pattern as well as the characteristic
b-sheet signals by circular dichroism (CD) spectrophotometry
and Fourier transform infrared (FTIR) spectroscopy. Following
this advance, it became possible to create amyloid fibrils from
many disease-related peptides such as Ab,59,60 hIAPP61 and
peptides related to larger amyloidogenic precursors such as
TTR.62 This paved the way for further structural characterisation
to reinforce the description of the amyloid core cross-b structure.
The cross-b pattern from ex vivo Val30Met variant TTR provided
a model structure, composed of repeating b-strands running
perpendicular to the fibre axis and associated to several sheets
that twisted with a helical pitch of 115.51.63 This model was
found to be representative of a collection of extracted amyloid
fibrils leading to the generic cross-b model for amyloid.64
Atomic force microscopy, transmission electronmicroscopy and
cryo-transmission electron microscopy (AFM, TEM and cryoTEM)
provided further macromolecular details and showed that amyloid
fibrils were formed of individual protofilaments65–68 and that
different precursor proteins may lead to different numbers of
protofilaments. It was also becoming clear that synthetic fibrils
grown under different conditions could lead to structural
polymorphism. For example, insulin fibrils analyzed by cryoTEM
showed multiple variations in the number of protofilaments
from two to six,69 while Ab40 was later shown to form even more
different classes.70 AFM was instrumental in demonstrating the
growth of the fibrils and generally showed that the diameters did
not change, but that the growth was additive elongation at the
growing ends.71
X-ray fibre diffraction from a short amyloidogenic region of
Ab11–25 gave exceptional detail and these fibrils were also analyzed
by cryoTEM to directly visualize the cross-b structure74 (Fig. 4).
High-resolution cryoTEM revealed striations that were 4.7 Å apart,
reinforcing the previous interpretation from the X-ray data and
providing new insights into the stability of the fibrils.74 4.7 Å
appeared to be the largest repeating unit and no long-range repeat
was apparent. Interestingly, later studies have shown quite
considerable variation in the helical twist for fibrils and often
very long-range repeats that can vary even within a single
filament. This variation goes some way to explaining why
longer-range repeats were not observed in diffraction patterns.
Amyloid fibrils are made from a large variety of precursor
proteins, ranging from the b-sheet sandwich structures of TTR,
immunoglobulin LC and b2 microglobulin, to the a + b structure
of lysozyme and the a-rich structure of serum amyloid A.55 Natively
unfolded proteins and peptides assemble in diseases such as T2D,
Fig. 4 X-ray fibre diffraction provides the characteristic cross-b pattern for
amyloid. Top panel shows a schematic showing the features of the cross-b
pattern and structure. Lower panels show the cross-b diffraction patterns
collected from amyloid fibrils formed by a diverse range of amyloidogenic
proteins and peptides. Ab11–25,72–74 AAAKKFFEAAAK,52 silk,75 hIAPP,76 NM
Sup35,77 ccb,78 Met30 TTR,79 Tau,80 Core PHF,81 b2M,82 Ab42,73,83
GNNQQNY,84 fibrinogen,85 RVFNIM.86 White arrow – major meridional,
H-bond spacing: 4.7–4.8 Å; grey arrow –meridional 2.4 Å; black arrow –major
equatorial, sheet spacing (10–12 Å; 5 Å for silk). Reproduced with permission
from ref. 72, copyright 2000 The American Chemical Society.72 Reproduced
with permission from ref. 73, copyright 2003 Elsevier.73 Reproduced with
permission from ref. 74, copyright 2000 Elsevier.74 Reproduced with permission
from ref. 52, copyright 2005 National Academy of Sciences.52 Reproduced with
permission from ref. 75, copyright 2007 Wiley-VCH.75 Reproduced with permis-
sion from ref. 76, copyright 2004 Elsevier.76 Reproduced with permission from
ref. 77, copyright 2000 American Association for the Advancement of Science.77
Reproduced with permission from ref. 78, copyright 2008 Elsevier.78 Repro-
duced with permission from ref. 79, copyright 1996 Ciba Foundation.79 Repro-
duced with permission from ref. 80, copyright 2003 National Academy of
Sciences.80 Reproduced with permission from ref. 81, copyright 2017
Elsevier.81 Reproduced with permission from ref. 82, copyright 2008 American
Society for Biochemistry and Molecular Biology.82 Reproduced with permission
from ref. 87, copyright 2012 American Society for Biochemistry and Molecular
Biology.87 Reproduced with permission from ref. 84, copyright 2010 Elsevier.84
Reproduced with permission from ref. 85, copyright 2007 Informa Healthcare.85
Reproduced with permission from ref. 86, copyright 2013 Portland Press.86
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AD and Parkinson’s disease (PD). Despite this diverse range of
starting native structures, all amyloid fibrils share the cross-b
structure and all precursor proteins, even those rich in b-sheet,
undergo a significant conformational change upon forming amy-
loid. Early work assumed that antiparallel sheets were formed
allowing different length polypeptide chains to access this repetitive
structure.72 Intriguingly, electroparamagnetic resonance pointed to a
parallel, in-register structure for amyloid fibrils formed from large
proteins and this appeared to suggest that the proteins needed to
unfold almost entirely to form a layer which then stacked to render
the fibrils.88 It seemed improbable, but structural models were put
forward showing a b-spine.89 It was not until the first solid-state
NMR (ssNMR) models were provided of Ab fibrils that it was shown
that the b-sheets were formed by bending of two strands that stacked
to assume a parallel, in register set of b-sheets.90,91 This structure,
held together by hydrogen bonding, provided a stack of identical
amino acid side chains along the length of the fibrils. It was clear
then, that the side chains played an important role in the structure.
X-ray and electron diffraction were combined to provide a model for
an amyloidogenic novel sequence AAAKKFFEAAAK, showing that
the side chains associated across the sheets.52,92
The first atomic-resolution X-ray crystal structures of amyloid-
like fibrils, formed in vitro from short adhesive segments of
amyloid-forming proteins, revealed the basis of amyloid stability
and provided atomic level insights into the amyloid core.19,94
The fibrils are formed from pairs of b-sheets, mated together by
interdigitation of their amino acid sidechains. This zipper-like
interdigitation of these structures suggested the term ‘‘steric
zipper’’ for this motif, which has now been found in numerous
X-ray, NMR, and cryoTEM structures19 (Fig. 5). In structures of
full fibrils, steric zippers are frequently found at junctions of
protofilaments (Fig. 5). Elsewhere in full fibrils, hetero zippers
(formed by two different sequences) are found. Factors contributing
to amyloid stability include: (1) the hydrophobic effect of releasing
water molecules from the tight, dry interface between the sheets;
(2) van der Waals stabilization of the interdigitating sidechains;
(3) mutual polarization of stacked amide hydrogen-bonding groups
parallel to the fibril axis;95 and (4) ladders of stacked sidechains
such as the phenolic groups of tyrosine residues on the surface of
the fibrils. The steric-zipper motif also explains the sequence
specificity of amyloid formation: only compatible sequences can
form steric zippers. Peptide inhibitors, designed on the basis of
crystal structures of short segments, are effective in inhibiting
aggregation and cell entry of full pathogenic amyloid fibrils.96
The technical challenge of determination of X-ray crystal
structures of amyloid fibrils is that the crystals are invariably no
larger than several microns in size. The hypothesis for the small
crystal size is that b-sheets normally exhibit a slow twist but are
held in amyloid crystals in untwisted form, producing a strain
that builds as the crystal grows, limiting size. In fact, the
crystals of the 11-residue NACore segment of aS are only a
few hundred nanometers in cross section, and hence invisible
by light microscopy. Consequently their structure had to be
determined by electron diffraction, for which small crystals are
advantageous.93 Yet, as it will be discussed later, the untwisted
form of amyloid crystals – compared to the twisted form of their
homologue fibrils – opens for a different way to further
decrease the overall free energy, placing them at the lowest
minimum of the free energy landscape.20
Thanks to developments in ssNMR and cryoTEM,103,104
numerous near-atomic-resolution structures of much longer
segments of amyloid fibrils are now available (Fig. 5 and 6).
ssNMR yielded structures for a 22-residue fragment of b2
microglobulin,105 Ab40 by 2008,106 for the more toxic Ab42 by
2016,97,98 and for aS fibrils.107,108 Further advances in cryoTEM,
largely helped by the invention of direct detectors and the
treatment of helical structures as single particles109,110 have
led to an explosion in atomic detail of amyloid structures. Near-
atomic resolution structures were solved for amyloid fibrils of
aS,111–113 Tau,101,114 and TDP-43.115 Paired helical filaments
and straight filaments from AD brain showed the parallel in
register structure with further exciting details at the bends
between the sheets. Tau filaments from chronic traumatic
encephalopathy patients114 and from Picks disease patients116
show intricate differences that may give us clues regarding the
differences between the diseases. Immunoglobulin LC amyloid,117
b2microglobulin,118 acute phase protein amyloid A (AA)119,120 form
similar core structures. Many proteins in the amyloid state are able
to assume a variety of structural folds termed polymorphs.
Despite the variety of molecular structures displayed by
amyloid proteins, they show common features. The proteins
mainly form extended b-strands, and these are bent into a series
of hairpin-shaped b-arches, and are confined essentially in a
2-dimensional slab or ‘‘layer’’. Backbone amide groups extend
their hydrogen-bonding CQO and N–H groups up and down,
parallel to the fibril axis, and the resulting hydrogen bonds stack
the layers into slowly twisting protofilaments (Fig. 5). Most often,
two or more protofilaments twist around each other, forming the
fibril, but some fibrils are built from a single protofilament and
some are formed from several protofilaments. The protein
structures remain ‘‘cross-b’’ displaying the expected distance of
4.76–4.78 Å between the hydrogen bonded b-strands which
generally run perpendicular to the fibre axis.
Whereas pathological amyloid fibrils tend to be so stable as
to be irreversible, considerably more labile amyloid-like fibrils
have been found to form from low-complexity domains of
proteins that participate in hydrogels and liquid–liquid phase
separation.121–123 These low-complexity domains are especially
rich in Gly, Ser, and Tyr residues, and poor in most apolar
residues. Short segments of these domains have been crystal-
lized and the resulting structures (Fig. 7) are similar to steric
zippers in that they show pairs of stacked b-strands. But these
weakly adhesive elements differ from steric zippers in that the
backbones are usually kinked, with more polar and apparently
weaker interfaces that account for the reversibility of the fibrils.
These mildly adhesive interfaces have been termed LARKS, an
acronym for low-complexity, amyloid-like, reversible, kinked
segments. LARKS may contribute to the interactions between
proteins with low-complexity domains that participate in tran-
sient subcellular bodies, such as stress granules.
Structural studies of amyloid and amyloid-like fibrils have
opened understanding of these pathological and functional
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architectures at the atomic level. The hope is that continued
studies will contribute to the development of diagnostics and
therapies for the numerous diseases associated with these
fibrils.
4. Mesoscopic structures of amyloids
and their position in the energy
landscape
The mesoscopic features of amyloids, obtained from rabbit and
human kidney tissues affected by primary amyloidosis, were
first described by Cohen and Calkins in 1959 with a negative-
stain electron microscope.53 The authors marveled that ‘‘in the
rabbit kidneys, the appearance of the amyloid was striking. . .
(showing) delicate filaments’’. Although limitation imposed by
sectioning prevented the precise delineation of fibril dimen-
sions, they appeared to range in length from 1200 to 5000 Å,
and in width from 50 to 120 Å. The biopsy specimen of
the patient with extensive primary amyloidosis also showed
wavy bundles of delicate fibrils in the electron microscope.
These correlated with the areas of amyloid as seen in the phase
microscope and in stained sections. The dimensions were
similar to the ones seen in the rabbit amyloid. The width varied
from 70 to 140 Å and long strands up to 16 000 Å were measured.
No cross-bundling was apparent. The amyloid in the kidney of
the patient with parenchymatous involvement also demon-
strated fine bundles of filaments similar to those noted above.
The mesoscopic structure of amyloid fibrils has since been
extensively characterized, primarily with TEM, cryoTEM and
AFM, and similar fibrils have been documented for amyloids
and amyloid-like entities including functional and patho-
logical amyloids as well as engineered peptide and protein
amyloids of various lengths as short as several amino acid
residues, with di-phenylalanine being likely a minimum motif
for fibrillization.7,124–126
The repeating 3D structures of these amyloids are composed
of many (usually hundreds to thousands) copies of a peptide/
protein. As discussed earlier, at the atomic level amyloids are
arranged in a one-dimensional ordered cross-b-sheet motif,
which consists of two or more layers of intermolecular
b-sheets that run along the fibril axis.127 The polypeptides often
Fig. 5 Atomic-resolution crystal structures of two adhesive segments and two amyloid fibrils of the protein a-synuclein associated with PD. Upper left:
Crystal structure of the PreNAC segment with sequence 47GVVHGVTTVA56 (the first T in this sequence is a hereditary early-onset disease mutation A52T).
The upper view is down the axis of this steric zipper, showing atoms with van der Waals radii forming a tight, dry interface. Upper right: Crystal structure of
the NACore segment with sequence 68GAVVTGVTAVA78. The center shows two amyloid-like fibrils formed by a-synuclein (aS). In the top of the left
center, one layer of the Rod polymorph is viewed down the fibril axis, showing that it contains two identical aS chains each bent into a double hairpin
shape. The two chains meet at a steric zipper formed by the PreNAC segments of the two chains. Identical layers are stacked on each other, forming a
two-protofilament, slowly twisting fibril. In the top right center, one layer of the twister polymorph is viewed down the fibril axis. The fold of the two aS
molecules is similar to that of the Rod polymorph but the two chains meet at a different point than those of the Rod polymorph. They meet at an interface
similar to that of the NACore crystal structure. That is, the steric zipper interfaces that pair the b-sheets in the crystal structures are similar to the
interfaces between paired protofilaments in the fibrils. Notice that the slowly twisting twister fibril is formed by stacking identical layers on each other,
with a slight twist. Reproduced with permission from ref. 93, copyright 2018 Springer Nature.93
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render unbranched fibrils, 6–12 nm in width and up to several
micrometers in length,128 and are in general composed of
several protofilaments.129 The protofilaments may twist around
each other but not exclusively in a left-handed fashion. Straight
fibrils composed of several filaments as well as right-handed
fibrils have also been documented, though rarely for the
latter.130 The left-handed twist is attributed to the underlying
b-sheet secondary structure conformation composed of L-amino
acid residues (correspondingly, amyloids composed of peptides
of synthetic D-amino acids are usually right handed), although
the transfer of chirality of amyloid fibrils across length scales is
not conclusively solved, since protofilaments of a given handed-
ness may merge to form mature amyloid fibrils of opposed
handedness.131 Irrespective of the final handedness, a full rota-
tion of a filament within a fibril may be in the order of tens to
several hundred nanometers requiring aB0 to a few degrees of
rotation per b-strand. This imposes a limitation on the twist
periodicity as the hydrogen bond network of the b-sheet impor-
tant for the stabilization of the 3D structure is slightly perturbed
by the twist.
In general, the twist of amyloid fibrils results from propagation
of the chiral b-sheet secondary structure to higher hierarchies,
and thus is intrinsically related to the topology of the fibrils; yet
extrinsic parameters have also been found to contribute to the
overall observed twist. For example, the charged side chains on
the fibrillar surface induce a torsion per unit length which is
directly proportional to the overall charge. Since the extent of this
kind of charge repulsion can be tuned by salt concentration and
composition of the buffer medium, the twist periodicity can be
manipulated by the salt concentration of the system under study,
as demonstrated for b-lactoglobulin first grown at a low ionic
strength and then exposed to a high ionic strength post
fibrillization.132,133 According to this scenario, the ‘‘electrostatic’’
contribution to the twist can be relaxed by screening electrostatic
Fig. 6 Example ssNMR and cryoTEM structures for amyloid fibrils. Upper panel: ssNMR structure of Ab42.97,98 Two S-shaped molecules of Ab42 (black
and gray) are related by a twofold axis (marked by a circle), which runs down the center of the fibril. The N-terminal 14 residues are disordered; one
possible conformation is shown here by dotted lines. Many of the known hereditary mutations are carried by residues located on the outer surface (red).
The surface hydrophobic patch formed by residues V40 and A42 (orange) may explain the greater rate of secondary nucleation by the 1–42 species
compared with 1–40.99,100 Bottom panel: CryoTEM structures of two amyloid fibrils of Tau.101 These two polymorphs of Tau amyloid fibrils were purified
from the autopsied brains of AD patients. In both polymorphs, individual Tau proteins form C shapes, as shown by the cartoon ribbons with arrows that lie
nearly in a plane perpendicular to the fibril axis. The protein layers are stacked up to form a protofilament. For each polymorph, there are two
protofilaments, but they meet at different interfaces. Steric zippers are noted in the straight filament polymorph. The b-helical feature is enlarged in the
right-hand panel where it is shown in yellow.102 Reproduced with permission from ref. 100, copyright 2016 National Academy of Sciences.100
Reproduced with permission from ref. 101, copyright 2017 Springer Nature.101 Reproduced with permission from ref. 102, copyright 2017 Annual
Reviews.102
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charges via the presence of salts or buffers, until nearly complete
untwist of the fibrils is achieved. The same scenario was observed
for the functional amyloid hormone b-endorphin grown in the
presence and absence of NaCl: while the fibrils were flat when
grown in salt, they appeared twisted when grown in the absence of
salt albeit displaying practically the same 3D atomic structure
resolved by ssNMR spectroscopy.134
The twist periodicity may vary between fibrils within the
same sample and, to some extent, even within a single fibril. In
the same sample there may be both straight fibrils as well as
twisted fibrils, sheet-like structures, as well as helical ribbons
(see below for definitions, as well as Fig. 8). These hetero-
geneous morphologies are at the core of the so-called ‘‘meso-
scopic polymorphism’’, which arises from distinct structures at the
atomic level (also referred to as ‘‘molecular polymorphism’’),113
distinct protofilament packings,113 local salt concentrations during
the nucleation events, or distinct nucleation sites on heterogeneous
surfaces. The origin of the polymorphisms is therefore attributed to
the (local) environmental conditions, but may also indicate a
kinetically trapped origin of the amyloid.135 Nonetheless, the large
amount of polymorphism that can be observed at the mesoscopic
level, as exemplified by Ab40, is regarded both a typical property as
well as a conundrum of amyloids.
In detail, the mesoscopic polymorphism of amyloid fibrils
includes various topologies which can be classified directly by
the mean (H) and Gaussian (K) curvatures of the amyloid fibril
surface, defined as:
H ¼ 1
2
c1 þ c2ð Þ; K ¼ c1c2;
where the two principal curvatures, c1 and c2, are the inverses of
the main radii of curvatures R1 and R2 describing the surface at
each point. Helical ribbons can approximately be wrapped
around a cylinder of radius R and at every protofilament,
the principal curvature are c1  1
R
; c2  0; helical ribbons
are therefore characterized by H  1
2R
; K  0. In twisted
ribbons, the situation is quite different. Bending of protofila-
ments is very small, and external protofilaments must describe
helical trajectories which introduce an increasingly large
stretching when moving from the center to the external proto-
filaments, as recently described in the context of the morpho-
genesis of other topological objects, including plant leaves.137
Since the mesoscopic bending of twisted ribbon amyloids is
minimal, these objects are well approximated by H E 0,
whereas K deviates from zero, due to a torsion which is a
function of the width-to-thickness ratio of the ribbon.138 Thus,
the twisted ribbon topology is well described by the geometry of
a helicoid, i.e. the ruled minimal surface in between the helical
trajectories of the two external protofilaments placed at a
distance R from the central axis. For such a ruled minimal
surface, H = 0 and K ¼  P
2p
,
P
2p
 2
þ R2
 !" #2
, where P is
the full pitch length (periodicity) of the twisted ribbon. Since in
amyloid twisted ribbons generally P c R,133,139 this can be
further approximated by H E 0 and K   1ðP=2pÞ2. The com-
bined negative Gaussian curvature and zero mean curvature
endow twisted ribbons with saddle-like topological features. In
contrast, flat ribbons and amyloid crystals (achiral, no twist)
both possess H = 0; K = 0 by definition. Nanotubes are
topologically similar to helical ribbons, and the exact relation
H ¼ 1
2R
; K ¼ 0 holds for them.
The overall elastic energy per unit length of amyloid fibrils is
a complex interplay of torsional and bending energies,20,21
whose contributions change differently with the lateral dimen-
sions of amyloid fibrils. As a consequence, different structures
of amyloid fibrils are found as a function of the number of
constitutive protofilaments: at a critical width to thickness ratio
or for a specific number of protofilaments, a transition from
Fig. 7 Atomic-resolution crystal structures of five LARKS contrasted with
the structure of a steric zipper from the segment with sequence NKGAII
from Ab. The right-hand column shows the paired b-sheets of the steric
zipper at the top and of the five LARKS below. For each structure, five
layers are shown of the thousands in the crystals, with the fibril axes
vertical. The view in the middle column is down the fibril axis and shows all
atoms of the interfaces. The view in the left column is also down the fibril
axis and shows the tracings of the protein backbones. The tight interface of
the steric zipper offers a strong interaction. The kinked interfaces of the
LARKS are weaker. Each interface is characterized by its shape comple-
mentarity score (Sc = 1.0 for perfect complementarity) and buried solvent-
accessible surface area (Ab) in Å2 between the mated sheets. Nitrogen
atoms are blue, and oxygen atoms are red.123 Reproduced with permission
from ref. 123, copyright 2018 American Association for the Advancement
of Science.123
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twisted to helical ribbons occurs,136 in analogy to the behavior
observed for chiral liquid crystalline films undergoing similar
transitions at a critical film width138 or leaves undergoing
identical twisted-helical ribbon transition for a critical differential
strain.137 In other words, in a twisted ribbon morphology, the twist
periodicity itself limits the number of protofilaments per fibril
possible, as the outer protofilaments must go a longer way around
the central one. A consequence of this fact is that the number of
protofilaments per fibril in a twisted ribbon is approximately
proportional to the twist periodicity and actually appears to be
proportional to the twist periodicity for fibrils with several
protofilaments.133,139 Conversely, in a helical ribbon, no universal
feature relating the periodicity to the number of protofilaments is
observed. This is because helical ribbons can close into nanotubes,
thereby reducing the line tension of external protofilaments by
virtually maintaining their mean curvature H unchanged and
rendering them a metastable precursor to nanotubes. Fibrils
composed of two to several protofilaments have been documented.
In the case of straight fibrils or helical ribbons, however, the
number of protofilaments or ribbons may increase significantly
towards a sheet-like entity composed of up to 10 or more filament
entities,136,140 with a record-large number of protofilaments in a
single flat amyloid ribbon reported for the case of the R3 fragment
of Tau protein.141
Recent studies of the elastic energies of twisted ribbons, helical
ribbons, nanotubes, flat ribbons and crystals21 have allowed posi-
tioning each of these polymorphs in a relative scale of energy (Fig. 9,
right panel). Specifically, the absoluteminimum in the free energy of
the protein folding landscape previously attributed to amyloid fibrils
has been refined into a series of relative minima where each
polymorph has a specific energy level.20,21 Twisted ribbons occupy
a relative minimum in the protein folding energy landscape and
must overcome a precise energy barrier to fully untwist and enter the
absoluteminimumoccupied by (achiral, untwisted) amyloid crystals;
helical ribbons need to overcome a larger energy barrier to fully
untwist and enter the same minimum as amyloid crystals: the extra
energy barrier compared to the amyloid twisted ribbons is provided
by the twist-bending coupling energetic term existing for helical
ribbons but missing for twisted ribbons. Accordingly, no helical
ribbon-amyloid crystal transitions have yet been observed, whereas
twisted ribbon-amyloid crystal transitions have been well
documented.20 Because the energy level of a fully untwisted helical
or twisted ribbon is equivalent, this places helical ribbons on a lower
energy level than twisted ribbons. Thus, rather than overcoming this
larger energy barrier, helical ribbons tend to further evolve by closing
into nanotubes, which are further down the energy level reduced by
the line tension associated with the external protofilaments found in
helical ribbons. Only flat amyloid crystals, for which the translational
symmetry associated with a lack of macroscopic chirality accepts
reduction of surface tension by lateral aggregation, are allowed to
(indefinitely) sink into an energy minimum funnel which is asso-
ciated with the ground state of the protein folding landscape.
A question rises spontaneously of why amyloid crystals
which are postulated the ground state in the protein folding
energy landscape, are so rarely observed in vivo. As already
observed by Adamcik et al.,21 the protein folding process in vivo
occurs in non-conservative energy ensembles, with energy
injected into and/or dissipated by the system during biological
processes and with chaperone proteins assisting protein fold-
ing. This is in stark contrast to in vitro processes, where the lack
of chaperone proteins and the closed (conservative) ensemble
allow revealing the presence of amyloid crystals.
5. Primary and secondary nucleation
The formation of amyloid structures from a solution of peptide
or protein molecules can be viewed as a phase transition where
Fig. 8 Structure of amyloid fibrils as a function of the constitutive number of protofilaments in HEWL lysozyme as observed by AFM. The number of
protofilaments is indicated in each panel. Up to 3 protofilaments, the fibrils remain straight and in a twisted ribbon configuration (H = 0). Starting from 4
protofilaments, amyloid fibrils change into a helical ribbon configuration, as revealed by the characteristic zig-zag contour shape associated with a non-
zero mean curvature (H a 0). Reproduced with permission from ref. 136, copyright 2011 American Chemical Society.136
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a more ordered phase is formed within a less ordered solution
phase. Much attention has focused on the very early stages of
the formation of the amyloid phase. In general, the formation
of a new phase can be triggered either through spinodal
decomposition or nucleation. Spinodal decomposition takes
place under conditions where the solution phase is unstable
and even small density fluctuations are amplified and the
formation of a new phase takes place very rapidly. By contrast,
nucleation takes place under conditions where the solution
phase is metastable rather than unstable; this situation arises
when the newly formed phase has a lower free energy than the
soluble phase, but kinetic barriers slow down its initial for-
mation. The early stages of amyloid formation have been found
to follow the physics of nucleated processes.142,143 The stability
of the amyloid phase is determined by the thermodynamic
solubility of the amyloid forming protein; this is the critical
concentration Cc that remains in equilibrium with the amyloid
phase, and is in turn directly related to the standard free energy
DG of transfer from the solution to the amyloid phase,
Cc = exp(DG/kBT), where T is the temperature and kB the
Boltzmann constant. As such, when the concentration of solu-
ble protein remains below the critical concentration, there is no
thermodynamic driving force for forming the amyloid phase.
When this threshold is exceeded, the amyloid phase is now
more stable than the solution phase, and slow nucleation
can take place. Once an initial fibril has been formed,
further monomeric protein molecules can add on at a much
faster rate, a feature which is common to nucleation-growth
phenomena in nature, a special case of which is nucleated
polymerization which results in elongated structures such as
amyloid fibrils.144
There is a rich history of studies focusing on elucidating the
principal features of nucleated polymerization. Much of the
early work was carried out in the context of understanding
the polymerization of cytoskeletal filaments, including actin
and tubulin, which have a similar linear geometry to amyloid
fibrils.146 Studies in the 1960s established the principal
features of this type of process, including the fact that for early
times t the increase in the aggregate massM follows generically
a polynomial behaviorMB tn, where n = 2 for simple nucleated
polymerization and can have a higher value when the nuclea-
tion process is multi-step in nature.146 An important feature of
this type of classical nucleated polymerization is that there is
only a weak lag phase due to the polynomial time dependence.
Commonly, however, for amyloid formation, the reaction starts
with a very marked lag phase during which no or only very low
concentrations of aggregates are detected. After the lag phase, the
growth and formation of new amyloid fibrils takes place rapidly; this
type of process has therefore the features of a highly cooperative
transition, where the presence of aggregates facilitates the formation
of further aggregates. A central challenge therefore in the mecha-
nistic studies of amyloid formation is to relate the macroscopic
observations of protein aggregation to the underlying microscopic
mechanisms. A powerful tool in this context is chemical kinetics, a
formalism that captures a series of molecular events into a rate law
that describes the overall progress of the reaction (Fig. 10A). Applica-
tion of chemical kinetics to protein aggregation has revealed that in
many cases the apparent high level of cooperativity originates from a
Fig. 9 (left) Schematic representation of the main mesoscopic polymorphs observed for amyloid fibrils and their approximate mean (H) and Gaussian (K)
curvatures. (right) Sketch of the protein folding landscape in the region around the amyloid minimum: different polymorphs occupy different energy
levels, with amyloid crystals populating the absolute minimum. The right panel is redrawn with permission from Adamcik et al.21 Reproduced with
permission from ref. 21, copyright 2018 Wiley-VCH.21
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non-classical secondary nucleation process.16,147,148 In secondary
nucleation, the existing amyloid fibrils act as catalytic surfaces
for the formation of new amyloid nuclei which can then grow
further themselves. This type of process was originally described
for crystal nucleation where under many conditions growing
crystal faces can favour the formation of new nuclei. Secondary
nucleation was also found to be the key process controlling
sickle haemoglobin polymerization,149 a non-amyloid related
pathological protein assembly process. It has now been identi-
fied as a key mechanism for the formation of amyloid fibrils
from systems as diverse as Ab40,147 Ab42,16 aS148 and hIAPP.150
Recent evidence suggests that the sites for secondary nucleation
and growth are distinct and that secondary nucleation takes
place preferentially at the sides of amyloid fibrils.151
The existence of secondary nucleation challenges a number
of intuitive assumptions about amyloid formation, and perhaps
most strikingly that of the nature of the lag phase. Indeed, under
conditions where secondary nucleation is a dominant factor, the
lag phase is only very weakly dependent on the time to form the
initial nuclei, but rather depends on the rate at which these
nuclei can grow through elongation and multiply through sec-
ondary nucleation.152,153 This observation implies that primary
nucleation can be very challenging to study in bulk systems as it
has only a very weak effect on the overall kinetics. This picture
changes, however, when aggregation takes place in very small
volumes, a regime that can be probed through droplet micro-
fluidics (Fig. 10B–D). Microfluidic experiments have allowed the
study of single nucleation events, as well as the rate at which
amyloid conformations of proteins can propagate in space and
time from the site of the original nucleation event.145
The role of secondary nucleation in the development of amyloid
diseases remains an active area of investigation. There are indica-
tions that this process could be key in generating toxic oligomers
that are responsible for neuronal death associated with the aggrega-
tion of the Ab peptide in the central nervous system.154 Indeed,
microscopy studies have revealed that the concentration of oligo-
mers is highest in the vicinity of higher molecular weight aggregates
such as plaques.155 If the formation of such oligomers was driven by
primary nucleation, their concentration would be lowest in the
vicinity of plaques as the latter can sequester monomer through
their growth, thus leaving less monomer available for primary
nucleation. Secondary nucleation, by contrast, is highest in locations
which contain both monomer and aggregates,16 in agreement with
experimental observations of oligomer localization in vivo. These
considerations highlight secondary nucleation therefore as a
potential new target for curtailing the accumulation of Ab oligomers
in vivo. Finally, it has become apparent that nature has evolved
molecular chaperones that are able to inhibit secondary nucleation
in a highly specific and effective manner.154 This inhibition has
furthermore been shown to lead to a significant reduction in toxicity
associated with protein aggregation, even when the overall concen-
tration of aggregates is not affected, as it significantly reduces the
concentration of oligomeric species.
6. The ‘‘oligomer hypothesis’’
The lack of tools that allow visualizing the different stages of
amyloid formation led initially to the thinking that amyloid
formation was a two-state process that involved the conversion
Fig. 10 Primary and secondary nucleation and their verification with microfluidics. (A) Illustration of the power of chemical kinetics to elucidate
microscopic mechanisms. Experimental data for the aggregation of the Ab42 peptide fitted to an integrated rate law where the dominant source of new
aggregates is, from left to right, primary nucleation, fragmentation and secondary nucleation, respectively. (B) Schematic illustration of the microfluidic
strategy to detect directly single primary nucleation events and monitor the aggregation reaction in both time and space. (C) Time-lapse microscopy of a
single microdroplet trapped in the array shown in panel B. (D) Schematic illustration of the primary and secondary nucleation events and subsequent
aggregate multiplication which can be measured directly in microfluidic experiments. Reproduced with permission from ref. 16, copyright 2013 National
Academy of Sciences.16 Panels B–D adapted from ref. 145, copyright 2011 National Academy of Sciences.145
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of soluble native proteins into highly ordered cross-b sheet
fibrillar structures, similar to the polymerization of tubulin
monomers into microtubules. Hence, the original versions of
the amyloid hypothesis stipulated that amyloid diseases were
caused by the formation and accumulation of amyloid fibrils
in the brain or other affected organs.156 However, several
consistent pathological observations suggested that amyloid
fibrils may not be the culprits and led to reconsideration of this
hypothesis.157–161 These observations include: (1) amyloid
fibrils derived from different proteins were found in the post
mortem tissues of individuals who died without exhibiting any
symptoms of amyloid diseases;162 (2) the amyloid load did not
always correlate with disease onset or severity; (3) several
studies did not find a clear correlation between the extent of
fibril formation and neurodegeneration in AD animal
models;163–165 and (4) therapeutic interventions that success-
fully cleared amyloid plaques in humans did not result in
reversal or improvement in clinical symptoms of AD.166,167
The emergence of these findings coincided with reports from
biophysical studies on Ab, the key component of amyloid
plaques, suggesting that amyloid fibril formation may be more
complex than initially thought and involves the formation of
protein assemblies other than the amyloid fibrils.
The ability to generate amyloid fibrils in cell-free systems has
provided unique opportunities to investigate and dissect the
mechanisms of amyloid formation. These studies, performed on
Ab peptides by the Teplow and Lansbury groups,168,169 revealed
for the first time that amyloid formation did not follow a two-
state mechanism but rather occurred through a series of soluble
oligomeric intermediates of variable size and morphologies. The
observation that these oligomeric intermediates disappeared
upon fibril formation suggested that they were on pathway to
amyloid formation. As of today, oligomers have been observed
during the fibrillization of nearly all amyloid-forming proteins,
suggesting that they are obligate intermediates on pathway to
amyloid formation.
Although the great majority of studies have focused on
characterizing oligomers that form on the pathway to amyloid
formation, increasing evidence suggests that oligomers could also
form through fibril-mediated mechanisms or during processes
aimed at promoting fibril clearance. Several studies have suggested
that oligomers could form during the disassembly or fragmentation
of fibrils or upon their interactions with membranes.170–172 The
surfaces of fibrils have also been shown to nucleate the forma-
tion of oligomers via secondary nucleation mechanisms.173,174
Furthermore, it has also been proposed that amyloid plaques
and proteinaceous inclusions may also serve as reservoirs for
toxic oligomers.175–179 However, whether oligomers are simply
sequestered during the formation of amyloid-rich deposits/
inclusions, represent the byproducts of cellular process aimed
at dissociating and clearing fibrils, or are formed within these
deposits/inclusions remains unknown.
Together, these observations sparked a huge interest in the
field because they offered a possible explanation for the lack of
correlation between amyloid load and disease onset or severity.
This gave rise to an alternative amyloid hypothesis, the oligomer
hypothesis, which stipulates that oligomeric prefibrillar inter-
mediates, rather than the amyloid fibrils, are the primary cause
of toxicity and cell death in AD, PD and systemic amyloid
diseases.
Oligomeric intermediates on pathway to amyloid formation
are by definition transient in nature, as already largely dis-
cussed above in the context of the protein folding landscape.
They do not accumulate and are usually converted rapidly to
higher order aggregates, and eventually to fibrils. Although it is
possible to capture and detect oligomers during the process of
amyloid formation using imaging techniques such as AFM or
TEM, isolation of such oligomers during the fibrillization
process has proven to be difficult for most proteins. To address
this challenge, several protocols have been developed to
enhance oligomer formation and/or slow their conversion to
fibrils by manipulating solution condition or the use of mutant
forms of the proteins that exhibit higher propensity to aggrega-
tion (e.g. Ab42 vs. Ab40 and variants linked to early onset or
severe forms of relevant amyloid disease). Other protocols
relied on the use of chemical or radical-mediated cross-
linking approaches to trap and/or stabilize transient oligomers
to facilitate their characterization or isolation.180–186
At the structural level, on-pathway oligomers tend to exhibit
a mixture of secondary structure contents,187–189 often domi-
nated by b-sheet conformations.190 Compared to amyloid
fibrils, oligomeric intermediates of most amyloid forming
proteins exhibit weak binding to the amyloid specific dyes
thioflavin T/S (ThT/S) and Congo red,191,192 suggesting that
they have not acquired the cross-b structure that is character-
istic of amyloid fibrils, although studies on Ab oligomers using
X-ray fiber diffraction have suggested that some oligomers
possess cross-b-like conformations.193 Unlike amyloid fibrils,
which despite their polymorphism still share a common core
structure, cross-b sheet, amyloid oligomers exhibit large differ-
ences in their dynamic properties and structural diversity,
suggesting that it is unlikely that one specific molecule or
antibody would recognize all types of oligomers formed by
one protein. In 2003, Kayed et al. reported that it was possible
to generate antibodies that not only recognized different types
of oligomers and but also oligomers derived from different
amyloid proteins (Ab, hIAPP, aS and Tau) and suggested that
amyloid oligomers derived from these proteins shared common
structural features.194 This hypothesis was supported by sub-
sequent findings showing that oligomeric preparations from
these amyloidogenic proteins were toxic to cells and neurons.
However, subsequent studies by Glabe and colleagues and
other groups revealed that the different aggregate and oligomer
specific antibodies stained different types of pathological
aggregates in the brain and that there was no universal anti-
body capable of recognizing all type of Ab oligomers.195–197
The heterogeneity and dynamic properties of the oligomers
have thus precluded studies aimed at resolving their structural
properties at the atomic level. Oligomers rapidly interconvert
between different forms and exhibit high propensity to transi-
tion to higher order aggregates, thus making it difficult, if not
virtually impossible, to isolate and investigate the structural,
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functional and toxic properties of a single oligomeric species.
Several attempts have been made to achieve this goal, but
without any success. The use of sequential chromatography
separation methods or other protein separation techniques has
enabled the generation of oligomer preparations that are
enriched in specific morphologies,169,187,198–201 but generation
of homogeneous preparation consisting of one oligomeric
species of a defined size and morphology has not been possi-
ble. This explains why, despite two decades of active research, it
has not been possible to ascribe toxicity to a specific oligomeric
entity or develop tools and strategies that target distinct types
of oligomers. Furthermore, the diversity of the protocols used
to produce oligomers, which leads to oligomer preparations of
different size, structure and morphology distribution, com-
bined with the lack of tools and methods that enable precise
assessment of oligomer heterogeneity, has made it difficult to
compare and reproduce results across different laboratories.
Despite these challenges, such oligomer preparations have been
used to gain insights into the dynamic properties of oligomers
and to elucidate the sequence and structural determinants of
oligomer formation and stability using solution and ssNMR,
hydrogen deuterium exchange methods and other biophysical
techniques.189,202–208
6.1 The amyloid pore
Among all the different types of amyloid oligomers and pre-
fibrillar aggregates that have been isolated, the only type of
oligomers that suggest a specific mode of action and mecha-
nism of toxicity are the annular pore-like oligomers, which have
been observed for most amyloid forming proteins. Annular
pore-like oligomers have been observed during the aggregation
of both disease-associated (e.g. Ab peptides,18,198,209 aS,
SOD1,209 exon1 of the huntingtin protein, Tau,210 TTR211 and
serum amyloid A212) and non-disease-associated amyloid form-
ing proteins.213–218 They have been found in the absence of
membranes and also upon addition to lipid bilayers or reconstitu-
tion of amyloid proteins and peptides with membranes. Further-
more, several AFM studies have provided direct evidence of
amyloid-pore formation in synthetic vesicles or membrane mimics
by several amyloid forming proteins.219–223 Their shape and dimen-
sions, combined with extensive literature demonstrating that Ab,
hIAPP and other amyloid proteins exhibit channel-like activity on
membranes,219,222,224–226 have led to the amyloid-pore/channel
hypothesis, which suggests that channel/pore formation represents
one of the key mechanisms by which oligomers cause toxicity and
cell death in amyloid-related diseases. Evidence in support of this
hypothesis comes primarily from in vitro studies. For example
(1) mutations linked to early-onset AD and PD promote the
formation of amyloid pores and increase the channel and
membrane permeabilization activity of Ab and aS; (2) mimicking
cellular stress conditions associated with neurodegenerative
diseases, such as oxidative stress and metal induced oxidation
also promotes the formation of annular pore-like structure;209
and (3) several amyloid oligomers exhibited channel-like activity
and size-selective membrane permeabilization.227,228 Structurally,
several studies have shown that amyloid pore oligomers or
oligomers that exhibit channel-like activity exhibited b-sheet
rich conformations that were distinct from that of mature
fibrils.187,229,230 Although different types of oligomeric preparations
of Ab induced calcium uptake and disruption of ion homeostasis in
cells, the exact mechanisms by which these preparations exerted
their effects on cellular membranes remain unclear.
6.2 Toxic oligomers
The search for a toxic oligomer species has been the focus of
active research in both academia and industry. The hope is
that identifying a specific toxic species will pave the way for
developing novel therapeutic drugs and antibodies that prevent
their formation, induce their disassociation or block their
activity. During the past two decades, many studies have shown
that amyloid oligomers induce different types of toxic insults
when added to different types of cells, organotypic slice cul-
tures or injected into rodent brains. The extent and type of
toxicity observed vary depending on the size distribution of
oligomers and the assay and model systems used to assess their
toxicity. However, for all amyloid-forming proteins, the nature
of the oligomeric toxic species associated with each disease and
their mechanism of action remain elusive. In addition to the
complexity and heterogeneity of oligomer preparations, the
lack of tools that allow monitoring amyloid oligomer formation
and dynamics in cells makes it very difficult to attribute any
toxic effects or phenotype directly to specific type of oligomers.
The great majority of toxicity assays are based on addition,
treatment or injection of in vitro oligomer preparations into
culture media or directly into the brain, and toxicity is assessed
hours to days or even months after treatment with oligomers.
During this time, the extent to which the oligomer preparations
retain their original properties or change their conformation
and structural properties in response to changes in their
environments remains unknown. Therefore, better understanding
of the structure–function relationship of amyloid oligomers
requires the deployment of assays that allow for rapid assessment
of the cellular responses upon treatment with well-characterized
preparations of different types of amyloid species.
6.3 Post-translational modifications
Post-translational modifications (PTMs) such as phosphoryla-
tion, proteolytic cleavage, nitration and ubiquitination play
central roles in the aggregation and pathology formation in
the majority of amyloid-related diseases, including AD, PD,
Huntington’s disease (HD), and prion diseases. Amyloid fibrils,
which are among the major constituents of these pathological
inclusions are subjected to different types of PTMs, which very
often co-occur on the same fibrils. Despite the fact that these
modifications are used as pathological markers and antibodies,
and assays targeting modified forms of pathological amyloid
fibrils are commonly used to assess pathology formation and
spread and to monitor disease progression, the role of PTMs in
regulating the different steps along the amyloidosis pathway
remains poorly understood. The roles of PTMs in amyloid
oligomer formation, dynamics and the transition to fibrils have
not been investigated. Indeed, all of the amyloid oligomer
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preparation protocols used to investigate amyloid oligomer
structure and toxicity are devoid of PTMs because they are
usually derived from recombinant and synthetic proteins.
Although several studies have reported on the use of oligomers
isolated from tissues, cells or model organisms, the biochemical
properties of these oligomers and whether or not they are post-
translationally modified have rarely been investigated. Given the
increasing evidence demonstrating that PTMs could significantly
influence oligomerization, amyloid formation and clearance, it is
crucial to devote more attention and resources to map the PTM
profiles of native oligomers from human tissues and biological
fluids and to assess their effects on oligomer formation, structure
and toxicity. It is reasonable to speculate that PTMs may act as
molecular switches for regulating the equilibrium between different
types of oligomers and/or transitions from oligomers to fibrils.
Recent advances in protein synthesis of amyloid proteins have
enabled site-specific introduction of single or multiple PTMs
into amyloid proteins such as Ab, aS, Tau, N-terminal fragments
of the HTT protein and the prion protein, among others. Such
homogeneously modified proteins can be prepared in milligram
quantities, which should enable generation of modified amyloid
oligomers with specific PTMs or patterns of PTMs, thus paving
the way to elucidate the role of PTMs in regulating oligomer
formation, stability, dynamics, and their transition to amyloid
fibrils.
6.4 Evidence for oligomer formation in vivo
Unlike fibrils which can be easily visualized and characterized by
several EM techniques in cells or in pathological inclusions,231–234
visualization of oligomers in pathological aggregates remains
challenging, as protocols for specific and efficient immunolabelling
of oligomers, including amyloid oligomer pores in vivo, in post-
mortem brain tissues or on biological membranes, are lacking.
Evidence for oligomers come primarily from: (1) studies demon-
strating lack of correlation between amyloid fibril formation and
toxicity, under conditions that favor fibrillization; (2) studies
employing oligomer-specific antibodies; and (3) detection of
HMW SDS-resistant oligomers by western blots.235 Even when
solution-based methods such as size exclusion chromatography
are used to isolate fractions rich in oligomers, estimations of the
size of oligomers are then made on the basis of SDS-PAGE analysis
of these fractions, due to the presence of other proteins. Further-
more, we have very limited insight into the biochemical and
structural diversity of oligomers in vivo and it remains unclear to
what extent the oligomers produced in vitro reproduce the land-
scape of conformational and quaternary structures of native amy-
loid oligomers. This is largely due to the fact that oligomers are (1)
meta-stable; (2) present in low abundance; (3) heterogeneous; and
(4) difficult to distinguish from other proteins in complex biological
environments.
Several assays and methods have been developed to measure
the level of oligomers in biological fluids, but the level of these
oligomers is usually too low to allow interrogation of their size
and conformational properties and thus these studies are
usually limited to correlating oligomer concentrations to disease
progression. One of the most commonly used oligomer-specific
immunoassays is based on using the same antibody to capture
and detect the amyloid protein of interest. However, these assays
do not differentiate between oligomers and fibrils and may not
provide an accurate quantitative assessment of oligomer levels
due to the lack of the proper calibrants or calibrants that capture
the diversity of oligomers in biological samples.
6.5 Targeting amyloid oligomers
The lack of correlation between amyloid fibril formation and
disease onset and severity in several amyloid diseases com-
bined with increasing evidence of amyloid oligomer toxicity has
led to oligomers emerging as one of the primary targets for
developing therapies to treat amyloid diseases such as AD and
PD. The field of amyloid oligomers and the toxic oligomer
hypothesis was initially driven by research on Ab peptides
mainly because (1) Ab oligomers could be populated in large
quantities; (2) validated protocols for producing Ab oligomers
were quickly developed and made accessible and; (3) the Ab
peptides were also readily accessible through commercial ven-
dors. Despite this, Ab preparations were still characterized by
great variability in terms of their size, structure and morphology
distribution. To reduce such variability or enrich oligomers of
specific size or structure, heterogeneous preparations were
further separated using different protein separation methods.
Nonetheless, several academic labs and pharmaceutical compa-
nies used such oligomer preparations to develop large number
of ‘‘Ab oligomer-specific antibodies’’, many of which advanced to
clinical trials, but none of which has proven to be effective in
significantly slowing or reversing the clinical course of AD.236–239
The same approaches have been extended to other amyloid
proteins such as aS and Tau,240–244 but with limited success
thus far, although several antibodies are still being evaluated in
different stages of clinical trials (more see Section 7).239,245,246
One possible reason for the failure of oligomer-specific anti-
bodies could be the fact that these antibodies may target only
one oligomeric form or subset of the different types of oligomers
that exist in vivo,247,248 or that post-translational modifications
on native oligomers may interfere with antibody recognition. To
address these limitations, it is crucial to gain more insight into
the biochemical and structural properties of native amyloid
oligomers and develop strategies that enable isolation and
characterization of as many native oligomeric species as possible
from patient-derived tissues or biological fluids.
7. Amyloidosis mitigation in vitro and
in vivo
Amyloidosis originates from protein misfolding, triggered by
protein metastasis and abnormal physiological conditions and
manifested by the production of protein aggregates possessing
rich polymorphism and evolving physicochemical properties.249
Amyloid inhibition, in essence, works against the downward
free-energy landscape of protein folding and aggregation250,251
by stabilizing disordered monomers, driving toxic oligomers and
protofibrils off pathway or sequestering them into elimination,
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and remodelling mature fibrils into biologically inert, amorphous
aggregates.
The past decades have witnessed active development of mitiga-
tion strategies against amyloidosis, involving peptidomimetics
(1990’s onwards),252 monoclonal antibodies (2000’s onwards),159
small molecules (2000’s onwards)253 and, more recently,
organic and inorganic nanoparticles and nanocomposites
(2010’s onwards) (Fig. 11).22,254 Specifically, peptide inhibitors,
such as the b-sheet breaker KLVFF,255 draw inspiration from
the structural characteristics of Ab256 to initiate hydrophobic
interaction with the latter and act in a chaperone-like manner.
However, enzymatic degradation and poor blood–brain-barrier
translocation are the notable undoing of this strategy. Monoclonal
antibodies, such as Bapineuzumab (Pfizer, J&J), Aducanumab
(Biogen, Eisai), Solanzumab (Eli Lilly) and Ponezumab (Pfizer) target-
ing the N-terminus, amyloidogenic fragment and C-terminus of
Ab,257–259 failed to pass phase-II/III trials and evoked the question
whether amyloidosis inhibition through peptide targeting and clear-
ance is a viable strategy against neurological disorders. Small mole-
cules identified by microarrays,260 such as 2,8-bis-(2,4-dihydroxy-
phenyl)-7-hydroxy-phenoxazin-3-one (O4),253 or derived from natural
compounds, such as epigallocatechin-3-gallate (EGCG),261,262 amelio-
rated the toxicities of Ab and hIAPP in vitro via inhibited (and,
occasionally, accelerated) aggregation. A major shortcoming with
small molecules, however, is their often limited water solubility
and, hence, low bioavailability and poor delivery efficacy.
Nanomaterials and multifunctional nanocomposites are
engineered/synthetic structures possessing versatile surface area,
functionality and architecture, and can be tailor-designed to alter
protein aggregation and match amyloid in size, morphology and
physicochemical properties. As a result, amyloidosis inhibition
with biocompatible/biomimetic nanoparticles and multifunctional
nanocomposites has become an emerging frontier, driven by the
rapid development of nanotechnology and accumulating knowl-
edge on nano–bio interactions.254 Simple polymeric nanoparticles,
such as dendrimers and star polymers, as well as condensed ceria
nanocrystals, graphene quantum dots, graphene oxide, gold nano-
particles, carbon nanotubes, transition-metal dichalcogenide
nanosheets (e.g., tungsten disulphide and molybdenum disul-
phide), multifunctional peptide–polymer nanosweepers, protein–
KLVFF–polymers, hIAPP19–29S20G and mesoporous silica nano-
composites, have shown potency inmitigating the amyloidoses and
pathogeneses of Ab, aS and hIAPP in vitro and in AD, PD and T2D
animal models.23,263–273 In recent years, it has been increasingly
realized that, as with molecular inhibitors, the endpoint of amyloi-
dosis mitigation with nanoparticles is not necessarily inhibition of
protein fibrillization per se, but suppression of protein toxicity.
Indeed, accelerated protein assembly may reduce the population of
toxic oligomers and protofibrils,253,274 analogous to Pmel17 aggre-
gation in melanin synthesis in the skin.275 However, no systematic
understanding is currently available to predict whether an exogen-
ous substance, nanoparticles included, inhibits or accelerates
protein aggregation, and if accelerated protein aggregation leads
to a beneficial or a detrimental effect on cell viability.
Experimental studies of amyloidosis inhibition often involve
a ThT or Congo red fluorescence assay to assess the cross-b
content and kinetics in protein fibrillization;276 TEM or AFM to
characterize the mesoscopic morphology of protein aggregates
(see Section 4); CD and FTIR spectroscopies to infer the peptide
secondary structure and their time evolution; NMR and beam-
diffraction (X-ray crystallography, EM) to reveal the atomic
structures of amyloid fibrils (see Section 3); gel electrophoresis,
dot blotting and immunohistochemistry to confirm protein–
inhibitor binding and amyloid/plaque formation; in vitro assays
to quantify cell viability and mitochondrial activity in conjunc-
tion with alleviated production of reactive oxygen species (ROS);
and in vivo assays to target and clear amyloid oligomers, fibrils
and plaques via autophagy,277 improve cognitive function and
mobility, and stimulate recovery of gene dysregulation.
Under in vivo conditions, inhibitors may be administered
through systemic circulation, or via direct injection into the
brain of transgenic mouse models in the cases of AD, PD and
HD. The peripheral circulation of nanoparticle inhibitors, for
example, may acquire a plasma protein ‘‘corona’’278 through
nonspecific adsorption, which ascribes a new biological identity to
the nanoparticle inhibitors to evade opsonization. Here, the design
usually aims at extending the circulation and improving the
delivery of the inhibitors. Upon binding with amyloid proteins,
nanoparticle inhibitors perturb the aggregation kinetics resulting
from nanoparticle–protein interactions in competition with
protein–protein self-assembly, mediated by hydrophobic inter-
action, hydrogen bonding and electrostatic interaction. A major
Fig. 11 Major anti-amyloidosis strategies with peptidomimetics, antibodies,
small molecules and nanoparticles/nanocomposites. The main purpose of
such intervention is to stabilize the monomers, suppress the population of
oligomers/protofibrils, or remodel amyloid fibrils. Such strategies have
shown, to various degrees, potency and failures against amyloidosis and
their associated toxicity in vitro and in vivo.
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indicator of strong amyloid protein–inhibitor interaction is
changes induced in the protein secondary structure, which
accordingly shift the high b-sheet contents of protofibrils and
fibrils to render disordered structures, coils, or alpha helices.
While this strategy may be easily demonstrated in test tubes or
cell cultures, binding of inhibitors with amyloid proteins
occurs far less frequently in vivo due to the much reduced
concentrations of amyloid proteins and inhibitors, environ-
mental pH, as well as binding of the interactants with other
intra- or extra-cellular proteins, chaperones/chaperone-like proteins
(such as serum albumin),279 enzymes, ligands, biometals,
membranes and other cellular organelles. Each type of inter-
action may influence the conformation and/or toxicity of amyloid
proteins and impact their associated pathogeneses downstream.
Furthermore, it has been shown that hIAPP amyloid fibrils, owing
to their strong capacity in initiating hydrogen bonding, can acquire
a protein corona in culture medium, enriched mostly by linear
proteins and multi-domain proteins of structural plasticity.280 The
immune response to corona-shielded amyloids and their precur-
sors, however, remains unclear. The nonspecific amyloid protein–
environmental protein association, further complicated by the
transient and heterogeneous nature of the toxic oligomeric species
(see Section 6) – with the exception of the structurally better defined
b-barrels which are unfortunately of a small population281 – implies
that morphology-based in vivo recognition of amyloid oligomers,
fragments or plaques may be inherently problematic. In addition,
the hallmarks of amyloid pathologies, such as inclusions and
plaques, are highly heterogeneous enriched by tens to hundreds
of types of proteins and metabolites,282–286 including extracellular
matrix glycoprotein serum amyloid P (SAP), which is thought to
stabilize amyloid from degradation,287–289 and membrane-bound
heparan sulphate proteoglycans (HSPGs), which mediate Ab
aggregation and cell uptake.290,291 The in vivo origin, dynamics
and mechanisms of such hetero-aggregation and cross-seeding
(see Section 8) are largely unknown, posing a tremendous
challenge to the design and implementation of amyloidosis
inhibitors targeting multiple amyloid proteins.
In addition to the aforementioned strategies, chiral mole-
cules292–294 or nanostructures,295 carbon nanotubes coated by
sonicated fragments of whey protein b-lactoglobulin,23 gold nano-
particles coated with milk protein b-casein,296 and polyoxometalate-
Dawson derivatives (POMDs) functionalized with histidine-chelating
metals (Cu, Fe, Ni, Co and Mn),297 have been utilized as inhibitors
against amyloidosis in cell cultures and with zebrafish models
(embryos, larvae and adults), exploiting the chirality of amyloid
fibrils, protein–metal coordination, chaperone-like inhibition of
protein aggregation, as well as functional-pathological double pro-
tein coronae mediated by hydrogen bonding and b-sheet stacking.
Zebrafish, in particular, have been validated as a high-fecundity
alternative to AD, PD and T2D (transgenic) mouse models,298–300
and are especially suited for testing a library of nanoparticle
inhibitors to render significant statistics at low cost and high
throughput. As multiple abnormalities occur in the homeostasis
of essential endogenous biometals,301 cellular delivery or libera-
tion of biometals (e.g., Zn2+ and Cu2+) with functional amyloids24
or metal-binding compounds302 may offer new breakthroughs
against amyloid diseases. Although not directly targeting amylo-
idosis, personalized antisense oligonucleotide (ASO) therapy against
a mutation in RNA-binding protein fused in sarcoma (FUS) is being
implemented to ameliorate a severe form of ALS,303 a motor neuron
amyloid disease. Furthermore, neurotrophic factor (NTF)-based
therapies, such as the delivery of cerebral dopamine neuro-
trophic factor (CDNF), have shown promise in stopping and
reversing neurodegeneration.304,305
8. Cross-seeding of amyloid proteins
Cross-seeding refers to the stimulation of aggregation of one
amyloid protein/peptide by another. Fig. 12 contrasts self-
seeding (homologous seeding) with cross-seeding (hetero-
logous seeding). This subject has been discussed in previous
reviews.306–310 In the following, we highlight a number of studies
which present important findings or address key challenges on
this topic. Cross-seeding has been observed for Ab with several
amyloid proteins including aS, Tau and prion protein PrP. This
may be relevant in vivo since co-deposition of Ab with PrP occurs
in amyloid plaques observed in brain sections from AD
patients.311 Studies using transgenic mice that overexpress the
amyloid precursor protein and which develop typical amyloid
(Ab-rich) plaques show that inoculation with prions leads to a
significant enhancement of both the onset of prion disease
symptoms and a concomitant increase in the level of misfolded
prion protein along with a notable increase in amyloid plaque
deposition.312 In the same study, in vitro fibrillization kinetics
assays also showed substantial acceleration of Ab42 fibrillization
by PrPSc (aggregated prion protein).312 In an early study, double
transgenic mice were developed that expressed Ab and aS in
neurons, displaying enhanced motor defects compared to single
aS transgenic mice andmore aS neuronal inclusions.313 Cell-free
studies also showed that Ab peptides promoted aggregation of
aS, and intra-neuronal accumulation of aS in cell culture.313 In a
similar fashion, exacerbated Ab, Tau and aS pathologies have
also been observed in studies using mice genetically engineered
to exhibit both AD and DLB (dementia with Lewy bodies, which
contain aS).314 This suggests that Ab, Tau and aS interact in vivo
to promote the aggregation and accumulation of each other and
accelerate cognitive dysfunction.314 These studies indicate that
Ab peptides may contribute to the development of Lewy-
body diseases by promoting aS aggregation and exacerbating
aS-dependent neuronal pathologies.
Different strains of aS (self-seeded or not) have a differential
effect on Tau inclusion in neurons.315 Both Ab and aS oligo-
mers cause Tau aggregation and lead to the development of
neurotoxic Tau oligomers that are rich in b-sheet structure.316
In vitro studies revealed that the A53T aS mutant enhanced the
fibrillization of both Tau and aS itself.317 It was therefore
proposed that such effects may be an important contributor
to the heterogeneity in amyloid characteristics and symptoms
among different individuals. Using the ThT amyloid fibrilliza-
tion kinetic assay and EM, cross-seeding of Ab40 or Ab42
and aS has been examined.318 The greatest enhancement of
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fibrillization kinetics was observed for cross-seeding with
fibrils of aS.318 Other amyloid forming proteins, such as the
DNA-binding protein TDP-43, can cross-seed Ab and suppress
the aggregation of the latter into toxic amyloid oligomers.319
Such oligomers are found in the brains of frontotemporal
lobar dementia, pointing to the important role of cross-
seeding in pathogenesis in this neurodegenerative disease.319
Cross-seeding has been demonstrated in vivo with Ab and
hIAPP.320,321 In vitro studies indicated that hIAPP fibrils are
poor seeds for Ab40 fibrillization (this paper also reported weak
seeding efficiency of Ab40 by a number of other peptides).320
On the other hand, preformed fibrils of Ab42 were injected into
hIAPP transgenic mice leading to hIAPP amyloid formation in
the pancreas.321 Co-localization was also observed with hIAPP
and pro-hIAPP (hIAPP precursor protein) being co-localized in
cerebral and vascular Ab deposits although in the converse
situation, Ab was not detected in islet amyloid from T2D
patients.321 Cross-seeding effects have also been studied for
the two different forms of Ab, Ab40 and Ab4287,322 and for point
mutants of Ab40 with Ab40.320
Cross-seeding of prion proteins from one species to another
has been suggested to be a mechanism behind the propagation
of specific amyloid strains.323 This has also been observed for
yeast prions such as Sup35 where the conformational switch
that led to domains rich in glutamine and/or asparagine such
as [PSI+] was promoted by heterologous proteins containing a
similar domain (as in several other yeast prions) or by over-
expression of proteins with prion-like Q-, N- or Q-/N-rich
domains.324 Mutual cross-seeding has also been observed for
Sup35 with the Rnq1 prion domain protein RnqPD, with extended
lag periods compared to the self-seeding processes.325 Hybrid
morphologies of Sup35 fibrils sprouting from globular RnqPD
structures and RnqpD spherical aggregates coated with Sup 35
seed fibrils were observed.325
Cross-seeding of subunits of insulin (A- or B-chain peptides)
with the parent protein was found to be less efficient than self-
seeding of the full-length insulin.326 The cross-seeded fibrils
had features of the parent insulin protein, the morphology
being distinct from that of the seeding peptides. Despite the
observed cross-seeding, soluble forms of the A- and B-chain
peptides were found to be able to inhibit insulin fibrilliza-
tion.326 In another study, it was suggested that cross-seeding of
hen lysozyme with other proteins was promoted by sequence
similarity.327 The ThT fluorescence kinetics were enhanced
for other forms of lysozyme compared to unrelated proteins
(insulin and a-lactalbumin), even though, for example, hen
lysozyme and a-lactalbumin share the same native state fold.327
9. Metabolite amyloidosis
While amyloid formation has been studied extensively with
proteins and polypeptides and even ultrashort peptides, a
major assumption in the field was that the minimal require-
ment for the formation of amyloid structures by a protein
fragment is a dipeptide.328 This is due to the unique planar
nature of the peptide bond, which stems from the electron
resonance in the structure that results in a partial double bond
between the alpha carbon and the amine nitrogen. To test this
assumption and following the extensive work on diphenylala-
nine (FF)124 and other self-assembling ultrashort aromatic
peptide such as triphenylalanine (FFF)329 and phenylalanine-
tryptophan (FW),124 the ability of a single amino acid, phenyl-
alanine, to form amyloid fibrils was evaluated.7 Surprisingly, it
has been found that at concentrations above 1 mM phenylal-
anine readily forms toxic fibrillar assemblies in aqueous solution
(as indicated by EM). The fibrils showed amyloid-characteristic
binding to ThT and green-gold birefringence between crossed
polarizers upon staining with Congo red.7 Moreover, it was
shown that antibodies could be raised against the assemblies
by immunization of rabbits and those antibodies could deplete
the toxicity of the amyloid-like assemblies by pull-down of the
toxic species.7
Following this unexpected discovery, there began an
immediate quest to understand its significance, which was
initially unclear considering the rather high concentration of
phenylalanine required for the self-assembly of amyloid-like
fibrils. While the normal concentration of phenylalanine in
healthy individuals is only a few tens of mM, there are affected
individuals with blood and tissue concentration of phenylala-
nine in the mM range. The medical condition is known as
phenylketonuria (PKU), which is the result of a mutation in the
gene coding for the phenylalanine hydroxylase enzyme.330
Individuals affected by the mutation are unable to convert the
phenylalanine amino acid into tyrosine. This results in the
accumulation of phenylalanine as well as an insufficient
amount of tyrosine. Intriguingly, unless treated by a very strict
diet, PKU patients show severe neurological symptoms similar
to neurodegenerative patients.331 After years of follow-up on
PKU patients and close monitoring of the correlation between
Fig. 12 Schematic contrasting homologous seeding with heterologous seeding where the seed oligomer (in red) stimulates the growth of oligomers
and ultimately fibrils of a different protein or peptide.308 Reproduced with permission from ref. 308, copyright 2013 Morales et al.308
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phenylalanine levels and neurological abnormalities, it is clear
that concentrations of phenylalanine above 0.5 mM are strongly
associated with severe neurological damage. To validate the
relevance of the observed phenylalanine fibrils to the disease,
their occurrence in mice model of PKU has been tested. Mice
have the same biosynthetic pathway for the production of
tyrosine as humans and a mutation in the same enzyme results
in the accumulation of the amino acid.332 It was indeed found
that antibodies which recognized the fibrillar assemblies, just as
in the case of the immunized rabbits, emerged spontaneously
in the model mice.7 Moreover, antibodies that recognize the
phenylalanine assemblies could allow the detection of phenyl-
alanine deposits in the brains of PKU patients post mortem.
These deposits are very similar to the amyloid deposits found in
those suffering from neurodegenerative diseases such as AD,
and could also be co-stained with the antibodies and Congo
red.7 Taken together, these results suggested a typical amyloid
etiology in PKU and an extension of the list of amyloid-
associated disorders.
Follow-up studies have been conducted to understand the
organization of phenylalanine into ordered assemblies and the
possible occurrence of oligomeric structures of phenylalanine.
Using mass spectrometry, Bowers and co-workers discovered
that under physiological pH phenylalanine could form oligomeric
structures, in which the phenyl groups were being exposed to the
solution.333 This interesting organization could be associated with
a tendency to interact with membranes as a result of the exposed
hydrophobic patches in the oligomeric form, as has also been
predicted theoretically by MD simulations,334 thus explaining the
high toxicity of the assemblies. An additional immediate follow-up
study by Salmona and co-workers indicates the organization of
phenylalanine into order assemblies using small angle and wide
angle X-ray scattering as well as AFM.335 Moreover, the researchers
show that doxycycline, a known protein amyloid formation inhi-
bitor, hinders effectively the formation of fibrillar assemblies by
phenylalanine.335
While phenylalanine accumulation in the case of PKU is
well-known, there are dozens of additional medical conditions
known as inborn error of metabolism disorders, in which other
metabolites are being accumulated.336 In order to test whether
the formation of metabolite amyloids in PKU represents a
unique case, a larger collection of other metabolites has been
screened for the ability to form amyloid-like structures. It was
revealed that additional metabolites, including tyrosine, orotic
acid, adenine, uracil and cysteine could form fibrillar assem-
blies with amyloid-like morphology, which bound ThT and
Congo red and presented notable cytotoxicity.337 Furthermore,
this broader study also demonstrates that the mode of toxicity
of these metabolite assemblies, as well as that of phenylalanine
assemblies, is by late apoptosis, exactly as in the case of protein
and polypeptide amyloids.337 Later studies indicated that addi-
tional metabolites, including tryptophan, glycine, and quino-
linic acid, could form amyloid-typical fibrillar assemblies in
aqueous solutions.338–340
Another interesting property of classical protein amyloids
that has recently been discovered is their intrinsic fluorescence
in the visible range of the electromagnetic spectrum, as was
shown by Kaminsky and co-workers.341 The researchers explain
the fluorescence by proton delocalization over terminal hydro-
gen bonds, which results in the formation of an essentially
supramolecular emissive electronic state. Intriguingly, similar
visible-range fluorescence has been observed for diphenylalanine
nanostructures.342 It has recently been established that metabolite
amyloids also possess such fluorescence properties, which also
allow their detection in live cells.343 The observed fluorescence of
the fluorescence in the context of hydrogen bond networks is also
in line with the crystal structure of phenylalanine in its zwitterionic
form at neutral pH, as was determined by synchrotron X-ray
crystallography in 2014.344 The structure shows a network of
hydrogen bonds and p–p interactions, layered with remarkably
similar morphology and zig-zag arrangement as compared to
protein b-sheet structures. Hydrogen bonds occur between polar
layers and the charged moieties of the amino acids, while edge-to-
face p–p interactions exist between the charged parts of the layers
and parallel displaced p–p interactions between the aromatic side
chains.344
Yet another property that is shared by protein and polypep-
tide amyloids and amyloid-like metabolite assemblies is the
generic inhibition by polyphenols and other aromatic
compounds.345,346 This common feature is also consistent with the
earlier observation concerning the inhibition of phenylalanine fibril
formation by doxycycline.335 Additionally, acetylsalicylic acid, which
does not affect the organization of protein amyloids, similarly has no
inhibitory effect on metabolite fibril formation.346 The metabolite
amyloids also exhibit the capacity to interact with membranes
similarly to protein amyloids, as determined by a highly-
characterized chromatic biomimetic membrane system containing
phospholipids and polydiacetylene.347 Also in this sense, the simi-
larity between metabolite and protein assemblies is remarkable.
The aggregation of metabolites appears to be directly linked
with neurodegenerative disorders. An intriguing observation is
related to the interplay between metabolite assemblies and the
induction of protein amyloid formation in the context of
seeding. It has been shown that phenylalanine fibrils could
seed a large group of amyloidogenic proteins and polypeptides
that are associated with amyloid diseases.348 It was suggested
that the presence of metabolite seeds could have a triggering
effect on the eruption of amyloid-associated neurodegenerative
disorders.349 Indeed, it was shown that quinolinic acid, a well-
established early marker of PD, could seed the aggregation of
aS into amyloid fibrils.340 This may provide the missing link
between the metabolite profile and the development of various
degenerative processes and may clarify certain unexplained
epidemiological associations.349
All of the experiments in metabolite amyloids until 2019
have been performed in vitro or in cell culture. It was recently
demonstrated that a yeast model of metabolite aggregation
could be constructed.350 By blockage of adenine salvage path-
ways, a yeast model in which adenine accumulates was
obtained. Feeding these model yeast with adenine exerted a
toxic effect in a non-linear sigmoidal-shaped dose-dependent
manner.350 Moreover, the addition of polyphenol inhibitors of
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amyloid rescued the yeast cells without lowering the level of
adenine, indicating that the formation of aggregates, rather
than the presence of a high concentration of the metabolite,
resulted in the cytotoxicity.350 As protein amyloid models in
yeasts have been extensively explored by many groups flowing
the pioneering work of the late Susan Lindquist,351 the current
use of yeast models allows to compare the cellular mechanisms
of protein homeostasis (proteostasis) and that of metabolite
homeostasis (metabostasis). The yeast system will allow further
analysis of the cellular machinery that is involved in the
response to abnormal accumulation of metabolites with and
without self-assembly into amyloid-like structures.
Finally, another interesting parallelism can be found between
protein and metabolite amyloids in the sense that as with protein
amyloids, functional assemblies that are composed of metabolites
can be formed.352 One key example is the formation of tapetum
lucidum, a retroreflector layer that facilitates night vision. These
assemblies are formed by simple metabolites that are very similar
tomajor human risk elements, including a nucleobase (guanine) in
reptiles, an amino acid (cysteine coordinated with zinc) in dogs,
and a vitamin (riboflavin) in cats and lemurs. Other studies
indicated the materials-like properties of amino acid assemblies
and the piezoelectric properties of amino acid crystals.353 The
overall organization of the metabolites in those systems seems to
be related to metabolite amyloids, highlighting once again the
similarity between the protein and non-proteinaceous self-
assembling systems.
Taken together, the spectrum of amyloid building blocks
appears to include not only proteins, polypeptides and short
peptides, but also a large number of metabolites (Fig. 13). The
full molecular determinants that facilitate the ability to form
amyloids are still unclear as very similar metabolites could
either form or not form amyloid-like structures. For example,
phenylalanine and tyrosine readily form amyloid-like structures,
whereas the structurally similar 4-hydroxyphenylpyruvate does
not. Additional work should be performed to fully understand
the structural, functional, and pathological significance of these
new type of non-proteinaceous amyloidal assemblies.
10. Systemic amyloidosis
Systemic amyloidosis is defined as an amyloid disease, in which
the synthesis of the fibril precursor protein and the deposition of
the fibrils occur at different sites within the body.354 The fibril
precursor protein is circulating in the blood, and the associated
fibrils form deposits in multiple organs, such as heart, liver and
kidneys. The deposits are often large-sized and exert physico-
mechanical effects that are a major factor of pathogenicity.355
For example, cardiac amyloidosis can compromise the natural
contractility and pumping function of the heart, leading to
severe cardiomyopathy.356 There is, however, evidence that toxic
fibrillization intermediates play a role in these diseases, similar
to their involvement in neurodegeneration. Systemic amyloido-
sis can cause major impairments to the affected patients, if not
death, and these diseases probably constituted the most abun-
dant protein misfolding diseases until the mid of the 20th
century. Nevertheless, they are nowadays much in the shadow
of their neurodegenerative relatives.
Several types of systemic amyloidosis can be distinguished
depending on the fibril precursor protein. This dependence is
reflected by the disease nomenclature.56 Systemic AA amylo-
idosis arises from the misfolding of SAA protein. Systemic AL
amyloidosis involves fibrils from immunoglobulin LCs, while
systemic ATTR amyloidosis originates from TTR fibrillization.
There are several commonalities among the different types of
Fig. 13 Formation of ordered fibrils and oligomers by metabolites. Malfunction of specific enzyme due to genetic mutation results in a significant
increase in the amount of specific metabolite substrate in the blood and tissues and lack of the metabolic product. In the case of PKU, the increase in
phenylalanine concertation is about 30–60 fold in PKU patients as compared to individuals with normal phenylalanine metabolism. The metabolite could
form fibrils or oligomers under physiological pH and the process could be inhibited by doxycycline or generic polyphenol amyloid formation inhibitors.
The assembled structures, most likely the oligomers, can interact with the membranes to lead to membrane destabilization and finally apoptosis and
damage to cells and tissues.
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systemic amyloidosis. The precursor proteins are either consti-
tutively or transiently present at high concentrations.354,356 They
are proteolytically truncated in the fibrils,354,356,357 and their
deposits are associated with non-fibril components, such as
glycosaminoglycans,358 lipids359 or non-fibril proteins,360 that
are conserved across different diseases and possibly important
for fibril formation358 or fibril stability in the tissue.355
Precisely 60 years after Cohen and Calkins revealed, with
electron microscopy, the presence of fibrils in the tissue,53
cryoTEM structures became available for amyloid fibrils that
were purified from the tissue of patients affected by systemic AA,
AL or ATTR amyloidosis.120,361–363 These structures revealed that
the fibril protein folds are, in all cases, substantially different
from their conformation in the respective native proteins. The
implication of this observation is that the conformation of the
native state has to be almost entirely unfolded in order to enable
the reorganization of the polypeptide chain into the fibril protein
fold. This conclusion holds even in cases where the fibril
precursor is b-sheet rich as in TTR.362 The fibrils that can be
extracted from a patient or animal are typically polymorphic with
one dominating fibril morphology.120,361–364 Consistent fibril
morphologies are deposited at different sites/organs of the same
patient or animal365 and even in different patients or animals, as
long as they belong to the same subtype of systemic amyloidosis
and possess the same sequence of the fibril precursor
protein.119,362,365
Current ways of treatment of systemic amyloidosis are
mostly focused on a reduction of the fibril precursor protein.
Treatment in systemic AL amyloidosis typically involves a
chemotherapy to remove the plasma cell that produces the
amyloidogenic LC.356 Treatment in systemic AA amyloidosis
involves anti-inflammatory treatments to reduce the serum
levels of the acute phase protein SAA.354 Treatment of systemic
ATTR amyloidosis can involve a liver transplantation to remove
the main TTR-producing organ.366 In addition, there are recent
advances to downregulate the expression of TTR protein by
RNA interference therapy.366 These treatments, which target
the precursor protein concentration, have to be combined, in
some patients, with the removal of the compromised organ. An
example hereof is the requirement of heart transplantation in
many patients with cardiac amyloidosis.356 Finally, certain
forms of systemic ATTR amyloidosis can be pharmacologically
treated with the drug tafamidis, which binds into the surface
pocket of TTR, stabilizing the native state of this protein.367
In summary, systemic amyloidosis represents an interesting
and unique model system for studying the principles of protein
misfolding diseases and for developing new medical approaches.
11. Bacterial functional amyloid
The preceding ten sections have focused on pathological amyloid.
However, there is growing awareness of the impressively useful
roles that the amyloid motif plays in many different biological
contexts. As discussed in a recent review,368 ‘functional’ amyloid
examples are found in many organisms, ranging from mammals
and insects369 to fungi and bacteria (though not yet plants –
possibly due to the many metabolites in plants which are able to
inhibit amyloid aggregation).370 Functional amyloids can partici-
pate in various cellular tasks, including serving as structural
scaffolds, with examples like Pmel17 in melanosomes, curli and
FapC in bacterial biofilms, and spidroins that enhance spider web
tensile strength. Additionally, peptide hormones can be stored
in an inert amyloid state,371 while amyloid formation by the
P. anserina HET-s protein regulates heterokaryon incompatibility,
transcription and translation can be regulated by prion proteins in
yeast.372 Because space constraints prevent a more detailed exposi-
tion of every functional amyloid, here we will focus on the bacterial
amyloid-forming proteins, CsgA and FapC. As functional amyloids,
they are produced as the result of highly coordinated biosynthetic
processes, and a great deal is now known about these biological
systems as well as the principles promoting their optimized
aggregation. Thus, functional amyloids serve as instructive exam-
ples of how nature can avoid the unwanted features of protein
aggregation and instead exploit the amyloid fold for cellular good.
A critical component of bacterial biofilm is the extracellular
matrix (ECM) that surrounds and protects cells. In many cases,
the ECM is strengthened by bacterially produced amyloid.373,374
The best-studied example is curli,375–377 produced by Entero-
bacteriaceae, such as Salmonella and Escherichia coli (E. coli), as
well as hundreds of diverse Gram-negative bacteria.378 Unlike
pathological amyloids, bacterial amyloids are functional (i.e.
biologically useful) and therefore produced as the result of
highly coordinated biosynthetic processes. Much can be
learned about the nature of amyloid formation by studying this
fascinating group of proteins.
Curli are required for proper biofilm development376,379–381 and
enhance biofilm strength, viscoelasticity, and resistance to
strain.382 The main component of curli, CsgA, is a 120-residue
IDP that is secreted into the extracellular milieu as an unfolded
monomer and was the first ‘functional’ amyloid protein to be
described.383,384 The minor curli subunit CsgB, also an IDP,
nucleates CsgA fibrillization as an amyloid template.385 Additional
CsgA subunits are added to the growing fibril end in a seeding
process.386,387 CsgB also helps anchor the fibrils to the membrane
surface via CsgF (in whose absence both proteins simply ‘‘escape’’
from the cell). Both CsgA and CsgB must be ‘‘chaperoned’’ to
suppress their high aggregation propensity and promote their
transport as monomers to and across the outer membrane prior
to amyloid fibril formation. They are secreted to the cell surface
through what is called the type VIII secretion system (Fig. 14), in
which CsgE targets them to the outer membrane secretion channel
CsgG388–391 via the two proteins’ N-terminal 22 residues.392,393 Once
polymerized, fibrils can interact with the dyes Congo red and ThT,
leading to a spectral change that is often used to monitor amyloi-
dogenesis. The resulting CsgA fibrils are unusually durable. Not
only do they resist heat, proteases, and denaturing agents such as
sodium dodecyl sulfate (SDS),394 they only dissociate to monomers
at very high concentrations (450%) of the potent denaturant and
solvent formic acid.395
CsgG is comprised of nine identical subunits, each lipidated
at the N-terminal cysteine residue to promote localization and
Chem Soc Rev Review Article
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
7 
Ju
ly
 2
02
0.
 D
ow
nl
oa
de
d 
on
 7
/1
4/
20
20
 1
2:
27
:4
2 
PM
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
Chem. Soc. Rev. This journal is©The Royal Society of Chemistry 2020
assembly in the outer membrane (Fig. 14).389,391 Each CsgG subunit
within the membrane-embedded CsgG homononamer contributes
four b-strands to a 36-strand transmembrane b-barrel, which sits
atop a ring of globular periplasmic domains. The structure contains
two vestibules separated by a series of constriction loops that restrict
the pore diameter to 9 Å.390,396 The first vestibule, formed by the
periplasmic domains, encloses B24000 Å3, roughly the predicted
volume occupied by a single unfolded CsgA monomer. The second
vestibule formed by the b-strands spanning the outer membrane
remains permanently open to the extracellular milieu, enclosing
B41 000 Å3. This is consistent with the need for subunits
to be largely unfolded during secretion into the extracellular
space.397 Besides binding and inhibiting the folding of CsgA,
CsgE also forms a functional nonameric cap that binds to the
CsgG pore and prevents unregulated transport across the outer
membrane.388,390,398 CsgE contains a mix of three stacked
b-strands, 2 a-helices, and a prominent IDR.398 Once CsgA is
confined to the space formed by periplasmic vestibule of CsgG
and the CsgE cap, it is thought that the resulting entropic free
energy gradient favors CsgA expulsion into the extracellular
space. CsgF and CsgB are also apparently secreted through CsgG.
A partial NMR structure of CsgF suggests it to be conformation-
ally dynamic with exposed hydrophobic regions. CsgF contains
an N-terminal unstructured region, a 21-residue a-helix, and a
C-terminal antiparallel 4 b-strands.399
According to ‘‘fishing expeditions’’ with amyloid-specific
antibodies, many bacteria produce amyloid,400 and numerous
operons coding for functional amyloid have been discovered
since curli (see an overview in ref. 401). Despite differences in
detail and independent evolutionary origins, there are common
features. These include one main amyloid component and a
secretion system to transport them to the outer membrane in a
monomeric state that is ready for extracellular assembly. For
example, the fap operon in Pseudomonas species directs the
formation of fibrils mainly consisting of FapC,402 assisted by
the (likely) nucleator FapB and transported through the outer
membrane by FapF.403 The ensuing fibrils increase biofilm
rigidity and resistance to drying out through increased
hydrophobicity.404 However, given their independent origins,
there will always be distinguishing features in each system. For
example, the membrane-embedded part of FapF is a trimeric
porin gated by a helical plug (much simpler than CsgG), while
its periplasmic coiled-coil domain could potentially guide
transport of FapC to the FapF channel as a dedicated ‘‘amyloid
shunt’’.405
The core of both CsgA and CsgB protein sequences is
composed of 5 imperfect repeated sequences (R1–R5), each of
around 20 residues.375 Peptides corresponding to R1, R5 and
R3 assemble into amyloid fibrils that are morphologically
indistinguishable from those produced by WT CsgA,406,407
whereas R2 and R4, which are largely dispensable for fibril
formation in vivo,406 do not fibrillate on their own. This
indicates that CsgA consists of multiple amyloid-forming
units, and indeed a combination of NMR data and secondary
structure predictions suggest that each repeat sequence in CsgA
forms strand-loop-strand motifs.393,408,409 Subsequently
co-evolutionary analysis combined with computational force
field analysis led to an atomic-level structure prediction in
which the 5 hairpins stack on top of each other to form an
a-helix,410 although the handedness of this helix still is unre-
solved in the absence of experimental restraints. The repeats in
CsgA are distinguished by the sequence Ser-X5-Gln-X4-Asn-X5-
Gln;393,406 the Gln and Asn residues in R1 and R5 are critical for
efficient amyloid formation393,406,411,412 while ‘‘gatekeeper’’
residues in R2, R3 and R4 slow CsgA amyloid formation both
in vivo and in vitro.411 The structural convergence of CsgA and
CsgB is rooted in amino acid sequence similarities, including
regularly spaced Ser, Gln and Asn residues.413
A similar situation is found with FapC, although it differs
from CsgA in that it contains 3 longer imperfect repeats
(B35 residues), separated by linkers of variable length. A
computational-bioinformatic structure prediction, similar to
that performed for CsgA, suggests that the FapC repeats form
hairpin loops, while the linker regions constitute disordered
regions that may lead to a ‘‘hydrophilic halo’’ around the
fibril.414 The advantage of this repeat-based design, both for
FapC and CsgA, is that each protein monomer constitutes an
amyloid-forming unit, which will facilitate rapid initiation of
fibrillization. No stable oligomers of either CsgA or FapC have
been isolated (except when assisted by fibrillization inhibitors
such as polyphenols415,416). This indicates that the repeat
structure efficiently drives fibrillization from a small and
stable nucleus and that there are no competing non-fibrillar
Fig. 14 Model of curli secretion. CsgE and CsgG facilitate secretion of
unfolded CsgA across the outer membrane. Outside the cell, CsgA
assembles into an amyloid via a nucleation precipitation reaction assisted
by CsgB and CsgF. The CsgE and CsgC proteins have been shown to
prevent CsgA aggregation in vitro. The CsgG nonamer is shown in purple,
and one of the CsgG subunits is colored green.
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structures, unlike e.g. the stable aS oligomer.417,418 Consistent
with this, fibrillization of both CsgA and FapC follows the
simplest possible model, namely primary nucleation followed
by elongation.419 This mechanism is ideal for the nucleation-
initiated elongation of bacterial amyloid fibrils in vivo, where
long (i.e. not fragmented) fibrils are likely required to
strengthen the ECM. Remarkably, step-wise deletion of the
repeats of FapC gradually increases the tendency of the fibrils
to fragment, and this means that elongation of the new growing
ends generated by fragmentation (rather than elongation of the
nuclei formed by primary nucleation) becomes the dominant
contribution to fibril growth.420 The resulting fibrils are also
more prone to dissociation in formic acid, a direct indication of
their reduced stability, and complete removal of all repeats,
while not preventing formation of b-sheet rich fibrillary
aggregates, catastrophically destabilizes the fibrils in terms of
sensitivity to denaturants such as formic acid and surfactants.421
A further twist on in vivo fibrillization is that biomolecules in the
milieu close to the outer membrane of Pseudomonas, such as
the biosurfactant rhamnolipid and the outer membrane compo-
nent lipopolysaccharide, strongly accelerate FapC aggregation
and suppress accumulation of a transient aggregation inter-
mediate.416 Thus, conditions have truly been optimized to facilitate
rapid and direct fibrillization of these proteins.
Amyloidogenic proteins present significant challenges to the
cell because of their strong tendency to aggregate. Uncontrolled
amyloid formation can upset proteostasis, and is associated
with significant cytotoxicity.422 Therefore, a fundamentally
important question is: ‘‘How can aggregation-prone proteins
such as CsgA be guided from the inside of the cell, through the
periplasmic space, and across the outer membrane so that
amyloid fibrils only form outside the cell?’’ The answer is:
accessory proteins such as CsgC, a small periplasmic protein
made by curli-producing bacteria that helps discourage intra-
cellular amyloid formation by CsgA and CsgB. Purified CsgC
can inhibit amyloid formation at extremely substoichiometric
1 : 500 (CsgC : CsgA) molar ratio, both for WT CsgA, R1, R3 or R5
CsgA deletion mutants, along with synthetic peptides corres-
ponding to R1 and R5. CsgC also inhibits amyloid assembly of
E. coli CsgA and CsgB homologs, but not the AD-associated protein
Ab42, suggesting some specificity.423 However, CsgC does inhibit
amyloid assembly by the PD-associated protein aS,423 possibly due
to a 8–9 amino acid motif (D-Q-F-X0,1-G-K-N-z) shared by both CsgA
and aS.423 Structural homologs of CsgC are found in almost all
bacteria.424 The CsgC structure can even be seen in the human
amyloid-forming protein TTR. Like CsgC, TTR can discourage CsgA
and aS amyloid formation.425 Therefore, it is likely that nature has
many anti-amyloid chaperone proteins at its disposal that can help
modulate amyloid formation.
Functional amyloids have much to offer going forward.
Amyloid-associated diseases affect an estimated 50 million
people annually. We need better approaches for combating
diseases such as AD and PD, which are twice as prevalent today
as they were 20 years ago, a number that could quadruple by
2050. The rules governing amyloid fibril formation have been
mostly defined through in vitro observations, because most
disease-associated amyloids aggregate inefficiently or sporadically
in vivo. It is not unreasonable to expect that next generation
amyloid therapeutics will be inspired by the mechanisms that
functional amyloid systems employ to temporally and spatially
control amyloid formation. At the very least, the N22-based display
system can be circumvented to target other amyloidogenic
proteins to the CsgG secretion channel and provide a bacterial
selection system for e.g. aggregation inhibitors.426 Furthermore,
the robust fibrils produced by these bacteria may serve both as
selectable display vehicles for e.g. peptides with different binding
properties427 and even as components in underwater glue when
fused with mineral-binding proteins such as mussel foot
proteins.428
12. Artificial amyloids and engineering
opportunities
In stark contrast to their original negative implications in
neurodegenerative diseases, but in line with the positive role
played by functional amyloids, artificial amyloids, that is amyloid
fibrils artificially produced in vitro from non-toxic affordable
proteins, have become a well-accepted building block of next
generation functional materials and nanotechnologies.26,429
Particularly noteworthy for advanced materials and technologies
are the following physical–chemical features of amyloid fibrils:
(1) their extreme aspect ratio; (2) the amino acid functionalities of
their surface chemistry; and (3) their Young’s modulus compar-
able to high performance commodity plastics. These features
have enabled unique and original applications of these systems
into a multitude of fields, some of which have now entered the
commercial realm. While the use of amyloid fibrils as templates
for innovative materials, devices and nanotechnologies has
already been discussed in detail in separate comprehensive
reviews,26,429,430 here we highlight briefly how the features
(1) to (3) of artificial amyloids allow their use in innovative
material design.
The extreme aspect ratio of amyloid fibrils provides unique
opportunities for assisting the self-assembly of materials tem-
plated by liquid crystalline interactions, for example. This has
allowed the design of 2D materials for optoelectronic and
biosensing applications, among others. The general strategy
followed is that the 1D excluded volume interactions of amyloid
fibrils can be exploited to drive the self-assembly of other
higher dimensionality anisotropic objects, such as 2D organic
and inorganic materials, starting at concentrations of the 2D
objects well below their intrinsic isotropic–nematic transition
composition. In other words, 2D objects can be ordered in their
dilute, isotropic state, when amyloid fibrils above their isotro-
pic–nematic transitions are present. In one example, amyloid
fibrils above the isotropic–nematic transition were used to
drive the alignment and stacking of graphene nanoflakes into
layered structures and finally 2D nanocomposites with uncon-
ventional sensing, shape-memory and biodegradable proper-
ties.431 This offered the first opportunity to design amyloid-based
devices for enzymatic biosensing.431 Similarly, replacing graphene
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nanoflakes with gold 2D single crystals allowed generating hybrids
materials with innovative optoelectronic properties, conductivity and
plasmonic properties.432 In a further example, inorganic gold single
crystals were replaced by ad hoc synthesized 2D hydroxyapatite
platelets, which once aligned by excluded volume interactions
into layered composites were able to mimic bone structure, with
amyloids replacing collagen fibrils.433 The further growth of osteo-
blasts onto these 2D hybrid materials brought the templates one
step closer tomimic real human bones.433 In the dense phase, liquid
crystalline interactions of amyloid fibrils were further used to design
solid films with anisotropic absorption and fluorescence proper-
ties;434 furthermore, although not directly demonstrated, the role of
highly anisotropic interactions and structure in amyloid-based films
may lead to improved quantum efficiency of semiconductive poly-
mers when embedded in amyloid solid matrices,435 as extensively
demonstrated by the Inganas group,436–438 among others.
In the liquid state, the liquid crystalline interactions of the
amyloids combined with their chiral nature have been recently
shown to be responsible for the formation of chiral nematic
phases, or cholesteric liquid crystals, in both a continuum
(bulk cholesteric phase) and dispersed state (i.e. cholesteric
droplets dispersed in a continuum isotropic phase).439 In both
the solid and liquid states, the concepts discussed above can
open the path to optical devices where the anisotropic nature of the
amyloid-based materials can be used to alter the orientation of an
electromagnetic field, as in filters for polarized fluorescence and
low-power liquid crystal displays, or the collective diffusion of
excitons or photons, in photovoltaic and organic/polymer light-
emitting diode (OLED/PLED) applications, respectively.
An alternative way to exploit the extreme aspect ratio of
amyloid fibrils is to generate gels, rather than liquid crystals,
where the high aspect ratio is now used to reach a gel phase at
extremely small percolation thresholds. This can be done by
simply altering the interactions among amyloids fibrils in the
colloidal state, by for example favoring attractive interactions
via changes in ionic strength (charge screening) or pH (altera-
tion of linear charge density).440–442 Amyloid-based gels of this
type have been shown to work as efficient scaffolds for cell
culture and growth, due to a noteworthy low cytotoxicity in the
greatest majority of cases investigated.443–446 Remarkably, this
spans over a wide range of amyloid building blocks, ranging
from the 10-residue 105–115 fragment from the protein
TTR,444,445 modified and engineered to carry the RGD integrin
binding sequence of fibronectin, to the much simpler amyloid
gels based on food proteins, such as lysozyme.447,448 These gels
have been demonstrated to be efficient means for cell prolif-
eration, to mimic the ECM environment, to perform tissue
engineering, and, when stem cell precursors are used, to
promote cell differentiation, as in the case of neural progenitor
cells differentiating into mature neurons during cell growth.449
Of particular significance in this case is the fact that small
variations in pH, ionic strength and concentration can result in
gels with significant changes in mechanical and rheological
properties.450 This is understood to be the playground in which
stem cell differentiation in vitro and in vivo occurs, and has
been demonstrated to date in several types of amyloid-based
gels of different amyloid sources, including peptides based on
Ab451 and aS.452
The amino acid chemistry decorating the surface of amyloid
fibrils further enables unique applications, some of which are
highly specific to these systems. Indeed, the presence of peptide
bonds opens for both versatile covalent and supramolecular
chemical approaches. Examples of covalent grafting of organic
moieties to amyloid fibrils include PNIPAM brushes grown from
b-lactoglobulin amyloid fibrils to produce injectable temperature-
responsive hydrogels;453 photo-induced cross-linking of the lipase
enzyme onto amyloid fibrils to produce biocatalysts with enhanced
enzyme stability;454 and DNA–amyloid conjugates in which DNA
provides the possibility of origami-driven colloidal assembly of
amyloid fibrils.455 Supramolecular interactions between metal ions
and amyloid fibrils have been shown to be particularly promising
for applications. Metal–ligand supramolecular binding is at the
origin of the strong adsorption of metal ions observed on the
surface of amyloid fibrils, mediated by strong binding to a multi-
tude of amino acids (see Fig. 15 for a schematic cartoon).25,456,457 By
exploiting this effect, Bolisetty et al. were able to produce amyloid-
based membranes for adsorption of heavy metals and radionu-
clides for efficient water purification.25 Due to the simultaneous
presence of diverse amino acids and thus, a multitude of metal–
ligand pair binding constants, these membranes act as ‘‘universal
sponges’’, challenging the highly specific exchange resins tradition-
ally used in water purification, for example. This has led to a
commercial application of membranes based on artificial amyloids
capable to remove a wide range of heavy metal ions such as gold,
Fig. 15 Schematic illustration of the binding process of gold ions with the
b-sheets of amyloid fibrils. The b-sheet structure is based on the molecular
dynamic simulations of the self-assembly process of the LACQCL
sequence, a fragment found on the b-lactoglobulin amyloid fibrils used
for water purification properties.25 Image rights: R. Mezzenga.
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platinum, silver, copper, lead, mercury, uranium, aluminium, and
even metalloids such arsenic.25,456,458
The concept has further been extended to remove halogen
contaminants from water, such as in the case of fluoride, by
first capturing transition metals on the fibrils, then growing
them in situ into fine transition metal nanoparticles, which
finally, by adhering to the amyloid surface, are capable of
binding targeted fluoride contaminants.459
The growth of metal ions on the surface of amyloids into
metal nanoparticles conjugated to the amyloid fibrils can be
further exploited for applications as diverse as heterogeneous
catalysis460 and human nutrition. For example, by growing
iron oxide nanoparticles from Fe2+ bound on the surface of
b-lactoglobulin amyloid fibrils, Shen et al.24 showed that the
resulting hybrids maintained iron at the right oxidation state
(i.e., the II form, which is more bioavailable than the III form),
which could then be used to target iron deficiency in vivo. The
authors further demonstrated that the b-lactoglobulin amyloid
fibril–iron oxide nanoparticle hybrids could be used as efficient
iron fortificants for nutrition purposes, with outstanding
bioavailability features. Alternatively, by growing noble metal
ions such as gold and palladium into nanoparticles, and using
b-lactoglobulin amyloid fibrils as a sole reducing agent, the
ensuedmetal nanoparticle–amyloid hybrids could be used to design
membranes for continuous heterogeneous flow catalysis.460
The scope of artificial amyloids can be expanded significantly
by combining some of the unique features discussed above:
amyloid gels can be combined with the reducing properties of
the amyloid fibrils to template gold aerogels with ultra-light
density;461 the reducing properties of amyloids can be used to
generate other types of oxide nanoparticles, such as TiO2 for dye
cell units for energy conversion;462 engineered amyloid fibrils
with specific binding sites can be used to target analytes and
specific molecules; for example, the Eisenberg group463,464 has
shown how amyloid templates can be used for efficient CO2
adsorption, thereby addressing another pressing environmental
issue. It is the multitude of features highly specific to amyloid
fibrils, which, when exploited synergistically, can give rise to an
extremely vast range of beneficial applications ranging from the
biomedical field, to environment preservation, energy manage-
ment and alike, serving modern society and shifting paradigms
away from the adverse tinge that amyloids have been mostly
known for.
13. Summary and future work
Much progress has been made in the field of amyloid science.
The atomic structures of extensively studied amyloid peptides/
proteins Ab42,465 Ab40,466 Tau101 and aS93,107,112 have been
resolved with improved in vitro fibril preparation and break-
throughs in cryo-TEM and ssNMR technologies. Such progress,
however, is contrasted by the lack of success in anti-
amyloidosis clinical trials and highlights this persistent ques-
tion: just how much amyloidosis contributes to cell degenera-
tion in amyloid diseases, alongside ageing, deficiencies in
microglial activation and peripheral clearance,467,468 as well
as other environmental and familial factors? The structural
characteristics of amyloid fibrils are essential for clinical classifica-
tion and, hence, the treatment of amyloid diseases. Indeed, while
distinct prion strains are associated with different clinical and
pathological phenotypes,469–471 variations in AD phenotype corre-
late with variations in Ab fibril structure.472–475 For example, among
AD clinical subtypes, the rapidly progressive form possesses rich
polymorphism of Ab40 fibrils, while the posterior cortical atrophy
variant and typical prolonged-duration form shows dominance of a
specific Ab40 fibril structure from seeded growth of AD brain cortex
extracts. On the other hand, all three subtypes displayed structural
heterogeneity for Ab42 fibrils.476 Clearly, amyloid structure offers a
basis for deciphering the often nuanced clinical manifestations of
amyloid diseases.
Amyloidosis occurs across different organs and biological
barriers in vivo, as exemplified by systemic ATTR, AL and AA
amyloidoses. On the other hand, amyloid proteins such as Ab,
aS and hIAPP have been detected in systemic circulation,
fuelling the hypotheses of cross-seeding, inflammation, the
gut microbiota and metabolite amyloid as causative to amyloid
diseases.5,477–479 Furthermore, Ab oligomers have shown a
negative effect on constricting human capillaries in AD via
signalling to pericytes.480 Accordingly, the structure and toxicity
profiles of amyloid proteins may be examined across different
compartments, physiological conditions and pathologies.
A major challenge in the clinical treatment of amyloidosis is
to ensure early diagnosis of the disease. In T2D, for example,
beta-cell mass accounts for only 1–2% of the pancreas but is a
key indicator of the onset and severity of the disease. Accordingly,
the development of molecular imaging probes and biomarkers
based on antibodies/nanobodies, RNA sequencing andmultimodal
detection is an identified area of clinical importance.481–483 Aside
from technological development, and in addition to solubility
and efficacy in delivery, the dose and timing of therapeutics
administration are crucial parameters for the treatment of
amyloid diseases. This is because amyloid proteins in vivo
undergo conformational changes on timescales vastly different
from in vitro test conditions, depending upon the age, mutation,
anatomy and body mass of the animal models. Fundamentally,
this challenge arises from the transient and highly hetero-
geneous nature of toxic oligomers and protofibrils, compounded
by cell membranes, pH, ligands and chaperones to influence the
protein aggregation energy landscape and toxicity. The evolution
of amyloid fibrils in physical and toxicological properties484 adds
another element of complexity for amyloidosis inhibition.
It should be noted that significant progress has been made in
recent years with regard to the clinical diagnosis and effective
management of systemic AL and ATTR amyloidoses. This is
achieved by mass spectroscopy identification, chemotherapy,
liver transplantation, gene sequencing, small-molecule (e.g.,
tafamidis and diflunisal) stabilization, antisense oligonucleotide
therapy as well as RNAi to mitigate the production or misfolding
pathways of amyloid proteins.485–487
Much remains to be understood concerning the structure–
function–pathogenesis relationship of amyloid proteins and
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their structural derivatives, as well as the co-aggregation and
cross-seeding of amyloid proteins with environmental proteins.
A large body of experimental evidence, particularly from genetics,
indicates that the proteins associated with amyloidosis are the
central player in pathogeneses. The toxicities of the oligomers and
protofibrils are indisputable facts of amyloid proteins. Amyloid
plaques first observed by Alzheimer in 1907 and their cross-b
structure first revealed by Eanes and Glenner a half century ago,1
are a major culprit for a wide range of debilitating human diseases
which remain to be deciphered and, hopefully, eradicated in the
coming decades.
Amyloids in current science and technology have evolved
significantly beyond their original strictly pathological roles,
taking up a novel original profile and illuminating new
opportunities which were unthinkable only two decades ago.
Two new classes of amyloids have emerged, the functional
amyloids and the artificial amyloids, performing challenging
and remarkably important roles in vivo as well as in modern
nanotechnologies. The unique structural and physicochemical
properties shared by pathological, functional and artificial
amyloids, have evolved from the debilitating role of the former
class in neurodegenerative diseases, to the beneficial tasks
played by the two latter classes of amyloids, with a demon-
strated and emerging role in modern technologies, and entail-
ing a wealth of applications in environmental remediation,
health, composite nanomaterials, energy devices, biosensors,
soft matter and 3D printing.26,428–430,488
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